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Take home message 
 
Managing hypercapnia may be an important intervention for improving the outcome 
 
 
of COPD patients with chronic respiratory failure. This ERS Task Force suggests the 
application of long-term home non-invasive ventilation to improve health outcomes 
by targeting a reduction in carbon dioxide in COPD patients with persistent 
hypercapnic respiratory failure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract  
Background 
While the role of acute non-invasive ventilation (NIV) has been shown to improve 
outcome in acute life-threatening hypercapnic respiratory failure in chronic 
obstructive pulmonary disease (COPD), the evidence of clinical efficacy of long-term 
home NIV (LTH-NIV) for management of COPD is less. This document provides 
evidence-based recommendations for the clinical application of LTH-NIV in chronic 
hypercapnic COPD patients. 
 
Materials and methods 
The European Respiratory Society Task Force (TF) committee was composed of 
clinicians, methodologists and experts in the field of LTH-NIV. The committee 
developed recommendations based on the GRADE (Grading, Recommendation, 
Assessment, Development and Evaluation) methodology. The GRADE Evidence to 
Decision framework was used to formulate recommendations. A number of topics 
were addressed under a narrative format which provides a useful context for 
clinicians and patients.  
  
Results 
The TF committee delivered conditional recommendations for four actionable PICO 
(target population-intervention-comparator-outcome) questions, (1) suggesting for 
 
 
the use of LTH-NIV in stable hypercapnic COPD; (2) suggesting for the use of LTH-
NIV in COPD patients following a COPD exacerbation requiring acute NIV (3) 
suggesting for the use of NIV settings targeting a reduction in carbon dioxide and 
(4) suggesting for using fixed pressure support as first choice ventilator mode. 
 
Conclusions   
Managing hypercapnia may be an important intervention for improving the health 
outcome of COPD patients with chronic respiratory failure. The TF conditionally 
supports the application of LTH-NIV to improve health outcome by targeting a 
reduction in carbon dioxide in COPD patients with persistent hypercapnic respiratory 
failure. These recommendations should be applied in clinical practice by practitioners 
that routinely care for chronic hypercapnic COPD patients.  
 
Introduction 
Scope and purpose 
Non-invasive ventilation (NIV) is increasingly being used as a long-term 
treatment in patients with hypercapnic chronic respiratory failure (CRF) due to 
various conditions [1,2]. While the role of acute NIV has been shown to improve 
outcome in acute life-threatening hypercapnic respiratory failure due to chronic 
obstructive pulmonary disease (COPD) exacerbations, the evidence of clinical efficacy 
of long-term home NIV (LTH-NIV) for management of COPD with hypercapnic CRF 
 
 
is less [3]. Thus, there is an ongoing discussion on whether LTH-NIV  should be used 
in COPD patients or not [4]. For this reason, the European Respiratory Society (ERS) 
created a Task Force (TF) to develop guidelines aimed at providing evidence-based 
recommendations on the application of LTH-NIV in CRF for patients with 
hypercapnic COPD. 
 
Materials and methods 
TF panel composition 
 The TF panel consisted of 15 clinical experts in the field of NIV and one 
clinical practice physiotherapist from ERS Assembly 2 Respiratory Intensive Care, one 
clinician representing ERS Assembly 4 Sleep and Breathing Disorders; and Clinical 
Physiology, one ERS methodologist (TT) and two clinician-methodologists (BR, SO) 
with experience in evidence synthesis and guideline development using GRADE 
(Grading of Recommendations, Assessment, Development, and Evaluation) 
methodology. During evidence to decision process, a representative (JB) from 
European Lung Foundation (ELF) provided COPD patient's perspective from the 
findings of their home mechanical ventilation survey [5]. 
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Question Generation 
 An initial list of PICO (target population-intervention-comparator-outcome) 
questions was developed by the TF chairs (RS, WW), which was discussed and 
prioritized in detail by TF members considering the clinical importance, availability of 
evidence, and patient perspectives. PICOs were then finalized at the September 2017 
TF meeting at the ERS conference in Milan. The TF selected six questions for the 
guideline to address, four PICO questions (Table 1), and two descriptive questions to 
be addressed in a narrative format, which the TF believed would provide useful 
contextual for clinicians and patients. 
 
Evidence summary and generation of clinical recommendations for PICO questions 
 Following the GRADE procedure, the TF rated each outcome for its perceived 
importance for clinical decision-making (from a patient perspective) on a scale of 1-
9, with mean scores of 7-9 indicating a 'critical' outcome, 4-6 indicating ‗important 
but not critical' and 1-3 indicating 'not important‘ [6]. The panel identified five 
'critical' outcomes, which would take priority in guideline decision-making for all 
PICO questions: mortality (short-term and long-term), hospitalization, COPD 
exacerbation, dyspnea, and health-related quality of life (HRQL). Data on non-critical 
outcomes (gas exchange, lung function, exercise tolerance, sleep quality) were also 
 
 
collected and considered, however not prioritized in recommendation generation. 
 For the four PICO questions, the two methodologists (SO, BR) conducted 
searches of the medical literature with the assistance of a medical librarian, drawing 
upon and updating literature searches for each PICO question from existing 
systematic reviews on the topic of LTH-NIV in COPD [7-9]. Medline, Embase, 
Cochrane CENTRAL, CINAHL, and Web of Science were searched from January 2014 
to January 2018 for English-language randomized controlled trials (RCTs) addressing 
the PICO questions. The search was updated in January 2019. The two 
methodologists screened the retrieved references for inclusion in the evidence 
summaries (Supplementary figure 1). 
  Data from retrieved studies was entered into Revman v.5.3 software. For each 
PICO, the methodologists, with input from the TF chairs, developed an evidence 
profile. Following GRADE principles, the TF rated the certainty of evidence for each 
outcome as ‗high,‘ ‗moderate,‘ ‗low,' or ‗very low.‘ The TF initially categorized the 
certainty of evidence for each outcome as high if it originated from RCTs and low if 
it originated from observational data. The quality of the evidence was subsequently 
downgraded by one or two levels if results from individual studies were at serious or 
very serious risk of bias [10], there were serious inconsistencies in the results across 
studies [11], the evidence was indirect [12], the data were imprecise [13], or 
publication bias was thought to be likely. 
 The TF developed recommendations for each PICO question by working 
 
 
through the GRADE Evidence to Decision Framework (EtD), which considers the 
quality of evidence, balance of desirable and undesirable effects, patient values and 
preferences, resource use, health equity, acceptability of an intervention, and 
feasibility of implementation [14,15]. Each recommendation was designated as 
―strong‖ or ―conditional,‖ using the phrasing ―we recommend" for strong 
recommendations and "we suggest" for conditional recommendations [16]. Direction 
and strength of recommendations was decided by consensus at an in-person 
meeting September 17, 2018 at the ERS International Congress in Paris. 
 
Manuscript preparation 
 Following the generation of recommendations, the TF divided up into working 
groups, which for each PICO question summarized the recommendation, provided a 
narrative summary of the evidence (highlighting the largest and most relevant 
clinical trials for each PICO question), issues raised in the EtD framework, and a 
justification for the final recommendation considering the above, along with 
implementation considerations and future research directions. Editing and feedback 
on the manuscript was conducted electronically, and coordinated by the TF chairs. 
The final wording of all recommendations and justifications was agreed upon the 
entire TF, and the final manuscript was submitted to the ERS for review and 
approval. 
 
 
 
How to use these guidelines 
 Due to limitations in the certainty of the available evidence, all four PICO 
recommendations are weak/conditional, and therefore require consideration of 
individual preferences, resource considerations, technical expertise, and clinical 
circumstances prior to implementation in clinical practice. While we have tried to 
consider a wide spectrum of such factors when making recommendations, we 
cannot account for all conditions. For each recommendation, we discuss evidence 
limitations, issues when moving from evidence to recommendations, and 
implementation concerns. By reading these guidelines, and considering their 
applicability to their current situation, we hope these ERS guidelines will help 
patients, clinicians, policy makers, and other health-care stakeholders to make 
rational, evidence-based, decisions with regard to the use of LTH-NIV in COPD, 
across a variety of settings. In table 2, we provide a high-level summary of how 
these guidelines can be applied [17,18]. 
 
Results 
 
Evidence summaries (including forest plots from meta-analyses) and EtD tables for 
each PICO can be found in Supplementary Material 1.  
 
  
 
 
PICO Question 1: Should LTH-NIV be used in stable patients with COPD as 
compared to not using NIV? 
Recommendation: The ERS TF suggests LTH-NIV be used for patients 
with chronic stable hypercapnic COPD (conditional recommendation, low 
certainty evidence). 
 
Background: COPD can cause both hypoxemic and hypercapnic CRF resulting in a 
high impact on mortality and economic burden of disease [19,20]. So far, long-term 
oxygen therapy (LTOT), which has been shown to improve survival, is the standard of 
care in COPD patients with hypoxemic CRF. COPD patients with chronic hypercapnia 
are more likely to be admitted to hospital, and once admitted experience a more 
rapid clinical deterioration [21,22]. The presence of hypercapnia has been shown to 
be a determinant of mortality [23-25].  
Correcting hypercapnia may be an important intervention aiming at improving 
the prognosis of these patients. NIV in this setting is increasingly being used [26,27]. 
The favorable impact of the reduced lung hyperinflation on respiratory muscles 
workload and the increased ventilatory chemo-sensitivity to carbon dioxide have 
been demonstrated as the main mechanisms that may explain the effectiveness of 
NIV in stable hypercapnic COPD patients [28-30]. 
 Many patients with advanced COPD have severe comorbidities (most 
importantly cardiovascular diseases), which independently impact their 
 
 
prognosis. Therefore, improving survival in hypercapnic COPD patients is 
challenging. The inconsistent results evident between early studies [26] are likely due 
to a number of factors, including heterogeneous patient populations (including 
different degrees of hypercapnia), different NIV ventilators, varied ventilator settings 
and interfaces, wide range of NIV application time and patient‘s compliance.  
In 2009, McEvoy et al. randomized 144 severe hypercapnic COPD patients 
either to NIV+LTOT or LTOT alone and demonstrated a slight survival benefit with 
NIV (median 28 months vs 20.5 months), but decreased HRQL [31]. The mean 
inspiratory positive airway pressure (IPAP) was 13 cmH2O and the mean expiratory 
positive airway pressure (EPAP) was 5 cmH2O, which corresponded to an inspiratory 
pressure support (PS, difference between inspiratory and expiratory pressures) of 8 
cmH2O. There was no decrease in partial pressure of carbon dioxide in arterial blood 
(PaCO2) level during follow-up. Subsequent clinical observation studies and 
randomized cross-over clinical trials reported that targeting maximal reduction of 
carbon dioxide by high inspiratory pressures and high back-up rates, or so called 
high-intensity NIV, improved gas exchange, lung function and respiratory muscle 
function [32-35]. A multicentre RCT included 195 patients with stable chronic 
hypercapnia (mean PaCO2 59mmHg in the NIV group and 58mmHg in the control 
group) and randomized patients to either LTOT alone or LTH-NIV in addition to 
LTOT ventilation targeting carbon dioxide reduction (mean IPAP of 22cmH2O with a 
mean EPAP of 5 cmH2O employed to decrease PaCO2 by at least 20% from baseline 
 
 
or to achieve PaCO2 < 48mmHg). Results showed a 1-year survival benefit in patients 
randomized to LTH-NIV  with an increase in HRQL [36].  
 Long-term prognosis following hospitalization in COPD is poor, with 5-year 
mortality rates of around 50% [37]. Therefore, one of the overall goals in the 
management of COPD is to minimize the number of disease-related hospitalizations, 
especially in those patients at high risk of developing hypercapnic acute respiratory 
failure (ARF). LTH-NIV, initiated when the patient is in stable condition, may reduce 
the number of future hospitalizations in these patients. Clini et al. reported that 
overall hospital admissions were lower in patients randomized to NIV and LTOT as 
compared with LTOT alone (-45% vs + 27%) [38]. In the study by Köhnlein et al., a 
decrease in emergency hospital admissions was observed in the NIV group when 
compared to the control group (2.2 and 3.1 exacerbation/patient/year, respectively) 
[36]. 
 
Evidence Summary: Overall 13 RCTs (Comparators to NIV are shown in the appendix) 
evaluated the effect of LTH-NIV on survival in stable hypercapnic patients with 
COPD; pooled analysis showed that NIV may have little effect on mortality (relative 
risk [RR] 0.86, 95% confidence interval [CI] 0.58-1.27, low certainty) [31,36,38-48] or 
hospitalizations (mean difference [MD] 1.26 fewer hospitalizations, 95% CI 0.08-2.59, 
low certainty) [36,38,49]. 
 Although the presence of hypercapnia is one of the primary indicators to 
 
 
prescribe LTH-NIV in COPD, data suggest only a limited effect of NIV on this 
outcome. The pooled data over 12 RCTs showed that PaCO2 decreased by 
3.37mmHg (95% CI 0.99 lower to 5.75 lower, moderate certainty) and partial 
pressure of oxygen in arterial blood (PaO2) increased by 3.09mmHg (95% CI 1.45 
higher to 4.74 higher, moderate certainty) following NIV therapy [31,36,39,41,43-50]. 
This minimal effect may be due to the fact that ventilator settings were not titrated 
to target normal PaCO2 levels. In a subgroup analysis of 5 RCTs in which NIV was 
used to target normal PaCO2 levels, the PaCO2 decrease was larger (4.92mmHg 
reduction, 95% CI 2.90 lower to 6.94 lower) [36,39,46-48]. There was no effect of NIV 
upon lung function as assessed by forced expiratory volume in one second (FEV1) 
(standardized mean difference [SMD] 0.07 higher, 95% CI 0.14 lower to 0.27 higher, 
low certainty) or forced vital capacity (FVC) (SMD 0.10 higher, 95% CI 0.06 lower to 
0.26 higher, low certainty) [31,36,38,39,41,44,46-48,50]. 
Dyspnea, exercise capacity, and HRQL are recognized as the most important 
patient-centered outcomes in COPD population. Pooled analysis of 5 RCTs shows 
that NIV may decrease dyspnea scores (SMD 0.51 lower, 95% CI 0.06 lower to 0.95 
lower, moderate certainty) [39,43,46,47,50]. NIV may improve exercise capacity and 
outcomes of pulmonary rehabilitation by resting chronically fatigued respiratory 
muscles, ameliorating lung mechanics, and daytime gas exchange [39]. Pooled 
analysis demonstrated an improvement in 6-minute walk distance (6MWD) (MD 
32.03 meters, 95% CI 10.79 to 53.26 meters, moderate certainty), which was higher 
 
 
than minimal important difference (26 meters) for severe COPD, in those using NIV 
[36,38,39,41,45-47,49-52].  
Seven RCTs evaluated HRQL with a follow-up period ranging between 3 to 12 
months; the pooled analysis demonstrated that HRQL was higher with NIV (SMD 
0.49 higher, 95%CI 0.01 lower to 0.98 higher, very low certainty) 
[31,36,39,43,46,47,50]. Included studies had to use one of the multiple validated 
scales/questionnaires in this population to assess HRQL. Whether NIV using high 
inspiratory pressure support values might be associated with higher HRQL remains 
unclear. In the multicenter study of Köhnlein et al, Severe Respiratory Insufficiency 
(SRI) Questionnaire summary scale score, general health perception subscale of 
Short Form 36 (SF-36) and St. George Respiratory Questionnaire (SGRQ) summary 
score improved more with NIV than with LTOT alone [36]. 
The effect of LTH-NIV on sleep quality has been studied to a lesser extent 
and only based on subjective assessments. Pooled analysis suggested sleep 
efficiency was slightly lower in those randomized to NIV (SMD 0.55 lower, 95% CI 
1.13 lower to 0.03 higher, low certainty), but the clinical relevance of this is unclear 
due to heterogeneous measurements of sleep [38,41,46]. Minor adverse events such 
as discomfort, skin damage, or rash were more common with NIV therapy (RR 10.35 
95% CI 2.45-43.71, low certainty) when compared to LTOT alone. However, most of 
these effects are interface-related and may be straightforward to manage [53,54]. 
 
 
 
Justification: The guideline panel decided on a conditional recommendation for NIV 
in the setting of stable chronic hypercapnic COPD patient. This recommendation was 
based on the evidence suggesting improvements in HRQL, dyspnea, and exercise 
tolerance. Even though the certainty in evidence for these outcomes was low to 
moderate, all were felt to be very important to patients. The evidence also 
suggested the possibility of small reductions in mortality and hospitalizations, with 
LTH-NIV, though there was significant imprecision in the pooled effects. Overall, the 
benefits were felt to outweigh the potential harms including minor adverse events. 
In terms of costs, frequent exacerbations and hospital readmissions account 
for the greatest part of economic burden in COPD patients, and economic data from 
the included trials suggest that NIV is cost-effective, especially in patients with 
frequent exacerbations and hospital admissions. Historically, LTH-NIV has been 
shown to reduce disease-related cost by decreasing the rate of outpatient visits, the 
hospital admissions, and the length of stay in the hospital [55]. The overall cost-
effectiveness of NIV therapy depends on further variables such as strategy for 
initiating NIV and close monitoring and follow-up including home care. LTH-NIV has 
evolved over the last 20 years and today's technology gives us the opportunity to 
monitor, even remotely, many physiological parameters by built-in software systems 
of NIV devices [56]. While in higher developing countries there has been a 
widespread use of LTH-NIV, in the countries with lower income economies, financial 
constrains may be a major limiting factor for patients who may benefit of LTH-NIV, 
 
 
including those with stable COPD [57]. 
 
PICO Question 2: Should LTH-NIV be used after an episode of acute hypercapnic 
respiratory failure in patients with COPD as compared to not using NIV? 
Recommendation: The ERS TF suggests LTH-NIV be used in patients with COPD 
following a life-threatening episode of acute hypercapnic respiratory failure 
requiring acute NIV, if hypercapnia persists following the episode (conditional 
recommendation, low certainty evidence). 
 
Background: 
  Severe COPD patients with chronic hypercapnia are most likely to experience 
re-hospitalization after a life-threatening episode of acute on chronic respiratory 
failure. These so-called ―revolving doors‖ patients, are often discharged with a PaCO2 
above 55 mmHg after a decompensated or compensated episode of respiratory 
acidosis due to COPD exacerbation on the background of at least two hospital 
admission episodes in the previous year [55,58]. 
 Four RCTs have evaluated the use of LTH-NIV after acute hypercapnic 
respiratory failure (AHRF) [59-62]. The first clinical trial randomized 40 patients with 
severe stable COPD (PaCO2 ≥55 mm Hg) after hospital discharge from AHRF to NIV 
or standard treatment for 2 years. The use of NIV was not associated with a 
 
 
reduction in mortality but improved several physiological (e.g. arterial PaCO2 and 
PaO2, 6MWD, mean pulmonary artery pressure), patient-centered (e.g. anxiety, 
depression, dyspnea) and healthcare centered (e.g. hospitalization rates) outcomes 
[59]. The second trial was a pilot RCT designed to compare continuation of NIV from 
hospital to home, with sham continuous positive airway pressure (CPAP) used as 
control, in severe COPD patients who had survived an acute episode treated with 
NIV and showed persistent hypercapnia at discharge (mean PaCO2 ~50 mmHg). A 
total of 47 patients were randomized and the proportion of patients developing an 
acute exacerbation during the time course of the study was statistically higher in the 
CPAP group. Of note, 8/23 (35%) of the LTH-NIV patients were withdrawn from the 
study before completion [60]. 
 Two larger RCTs investigated the clinical efficacy of NIV as a bridging 
treatment from hospital to the home following a life-threatening exacerbation of 
COPD requiring acute NIV. In the RESCUE trial, 201 COPD patients admitted to 
hospital with a life-threatening episode of AHRF and prolonged hypercapnia (mean 
PaCO2 ~48 mmHg) greater than 48 hours after termination of ventilatory support 
were randomized to NIV in addition to LTOT or LTOT alone. After one year, there 
was no difference between the two groups in the primary outcome of time to 
readmission or death. Although NIV was effective in reducing daytime and night-
time PaCO2, a similar reducing in PaCO2 was observed in the control group [61].  
 
 
 The HOT-HMV trial studied 116 COPD patients with persistent hypercapnia 
(PaCO2 >53mmHg) at 2 to 4 weeks after a life-threatening episode of acute on 
chronic respiratory failure treated with acute NIV, were randomized to receive LTH-
NIV, in addition LTOT, or LTOT alone. The NIV+LTOT group, compared to the LTOT 
group, resulted in an increased time to readmission or death within 12 months (4.3 
months vs. 1.4 months) [62]. 
 It is difficult to translate the results from the earlier studies into advice for the 
practicing clinician due to the small sample sizes, lack of standard definition of acute 
COPD exacerbation, and lower pressure support levels compared to the later studies. 
However, major clinical interest was raised by the latter trials, which despite similar 
trial design and primary outcome measure had differing results in terms of 
admission-free survival. It is likely that the higher level of PaCO2 at enrolment (mean 
48 mmHg vs. 53 mmHg), the higher exacerbations rate prior to enrolment and the 
timing selection of patients with persistent hypercapnia at 2-4 weeks following a life-
threatening exacerbation were major determinants of the enhanced outcome in the 
HOT-HMV trial. Conversely, the early within-hospital assessment of hypercapnia in 
the RESCUE trial may have led to the inclusion of a subset of patients with 
spontaneously reversible hypercapnia who do not take benefits from LTH-NIV 
treatment and consequently a better prognosis. The trajectory of recovery of 
hypercapnia is likely to have an influence on the outcome and the timing of this 
recovery needs clarification [24].  
 
 
 Another RCT evaluated the effects of stopping NIV after 6 months post-
hospitalization, finding that patients who remained hypercapnic after 6 months of 
therapy had clinical worsening and reduced 6MWD after stopping NIV, compared to 
those who continued, indicating the importance of careful selection of patients who 
will continue to benefit from LTH-NIV [63].
 
Evidence summary 
 Use of LTH-NIV after ARF was not associated with a reduction in mortality (RR 
0.92, 95% CI 0.67 to 1.25, low certainty), but may reduce exacerbations (SMD 0.19 
SD, 95% CI -0.40 to 0.01 SD, low certainty) and hospitalizations (RR 0.61, 95% CI 0.30 
to 1.24, very low certainty) though the study by Cheung et al, at high risk of bias, 
and with unclear definition of acute exacerbation, makes interpretation of these 
outcomes difficult. Reassuringly, sensitivity analysis excluding Cheung et al. does not 
significantly affect the conclusions made for these outcomes. Similarly, NIV may be 
associated with improvements in dyspnea scores measured using Medical Research 
Council Dyspnea score (MD 0.8 points lower, 95% CI 2.17 lower to 0.58 higher, low 
certainty) and HRQL measured using SRI (MD 2.89 higher, 95% CI 1.03 lower to 6.8 
higher) but these results are limited by imprecision and are of low certainty. NIV 
likely reduces PaCO2 (MD -3.41 mmHg, 95% CI -4.09 to -2.73, moderate certainty). 
Justification of recommendation 
 The recommendation was primarily based upon the desirable effects of LTH-
 
 
NIV after a life-threatening episode of acute on chronic respiratory failure, which 
suggest a small potential reduction in exacerbations and hospitalizations, though the 
overall certainty of evidence is low, primarily due to imprecision as well as 
reservations about the risk of bias. The TF considered indirect evidence from PICO 
Q1 with regard to minor adverse effects and resources required to help to inform 
the recommendations here, and noted that reassuringly similar desirable effects of 
NIV were seen in the COPD population both in stable (PICO 1) and in post-ARF 
phase (PICO 2), with few undesirable effects seen. Other outcome data from PICO 
Q1 was used for Q2 analysis or recommendation generation. Similarly the TF 
considered that the potential significant variability in values and trade-offs between 
mortality and HRQL with the use of NIV may play a role in shared decision-making 
about its use in this population, and ultimately the acceptability of NIV as an 
intervention. The TF considered the resources used similar to that in PICO Q1, 
though the feasibility of initiating NIV post-exacerbation may be higher, as in some 
centers clinical pathways exist post discharge to facilitate initiation of LTH-NIV. 
Considering all of the above in light of the limitations of the evidence, the TF panel 
chose to make only a conditional recommendation for the use of LTH-NIV after ARF. 
Lastly, there was discussion that patients may continue to improve for several weeks 
post-exacerbation; for this reason, reassessment of hypercapnia 2-4 weeks after the 
initial episode, as was done in the HOT-HMV trial, could be considered to identify 
those patients who are most likely to benefit from LTH-NIV. 
 
 
 
PICO Question 3: When using LTH-NIV in COPD patients, should NIV settings be 
titrated to normalize or at least cause a significant reduction in PaCO2 as 
compared to titrating not according to PaCO2 levels? 
 
Recommendation: The ERS TF suggests titrating LTH-NIV to normalize or reduce 
PaCO2 levels in patients with COPD (conditional recommendation, very low 
certainty evidence). 
 
Background:  In the last two decades, a number of published RCTs aimed at 
exploring the role of LTH-NIV in those with hypercapnic COPD, however most did 
not specifically target normalization or significant reduction in PaCO2 or directly 
address nocturnal alveolar hypoventilation. High-intensity NIV, a form of pressure-
limited controlled ventilation, that combined stepwise titration of IPAP up to 30 
cmH2O with an high back up rate just below the patient‘s spontaneous breathing 
frequency, was introduced as a novel therapeutic option in an attempt to maximally 
decrease elevated PaCO2 to normal levels and, at the same time, to achieve the total 
control of the patient‘s spontaneous respiratory activity aiming for substantial rest of 
the diaphragm [35,64,65]. Given to the greater capability of correcting nocturnal 
alveolar hypoventilation, high-intensity NIV has been reported to be more efficient 
in terms of clinical and physiological benefits (reduction of nocturnal and diurnal 
 
 
PaCO2 levels; improvement in FEV1, patient-reported exercise-related dyspnea score, 
6MWD and HRQL) than conventional ―low-intensity‖ NIV. Paradoxically, delivery of 
higher levels of pressure support was associated with better compliance to the 
treatment, probably as consequence of a greater subjective benefits perceived by 
chronically symptomatic patients [64-67]. 
 A strategy based on the combination of high pressure support levels and low 
backup rate –termed ―high-pressure‖ NIV- has been shown to provide the same 
physiological and clinical improvement in stable hypercapnic COPD compared with 
―high-intensity‖ NIV, suggesting that the use of a high backup rate is not necessary 
to achieve these benefits in such patients [67]. However, the number of patients in 
this study was considerably small requiring further investigations.  
 In consideration of the greater hemodynamic impact of ―high-intensity‖ NIV as 
compared to ―low intensity‖ NIV - positive intrathoracic swing pressures-induced 
decrease in right heart preload and elevated lung volume-induced increase in 
pulmonary vascular resistance, detrimental cardiovascular effects (i.e. reduced cardiac 
output) could develop under very high IPAP levels in very selected phenotypes of 
COPD patients especially if pre-existing severe cardiovascular diseases coexist 
[64,65]. However, the clinical significance of these effects needs further evaluation. 
Although it appears that high inspiratory pressure NIV leads to a reduction in 
hypercapnia, the impact on some patient important outcomes, such as sleep quality, 
is less certain [66,67]. 
 
 
 Finally, it should be considered that the definition of hypercapnia used 
amongst the studies targeting NIV to PaCO2 normalization in stable hypercapnic 
COPD patients was quite different, sometimes with very low mean baseline PaCO2 
levels [61]. Independently from the baseline degree of hypercapnia, a normalization 
of elevated PaCO2 levels is unlikely to be achieved in all COPD patients even under 
high IPAP levels.  
 
Evidence Summary: Even if one short-term trial reported physiologic benefits of NIV 
targeted to reduce chronic hypercapnia, we did not find any long-term RCTs directly 
comparing LTH-NIV strategies targeting PaCO2 reduction in those with chronic 
COPD versus those that did not. For this reason, to address this question, we 
considered subgroup analysis from PICO 1 comparing studies that targeted 
normalization of PaCO2 as compared to studies that did not target normalization.  
 Pooled analysis of five RCTs demonstrated that while ―high-intensity‖ NIV 
decreases PaCO2 levels at 6 weeks (MD -4.93 mmHg, 95% CI -7.43 to -2.42, low 
certainty) as compared to ―low-intensity‖ NIV, there was no effect on HRQL as 
assessed by the SRI (MD 0.95 points higher, 95% CI 8.33 lower to 6.42 higher, low 
certainty) in the ―high intensity‖ subgroup [34,64-66]. There was no effect 
demonstrated with  ―high-intensity‖ NIV on FEV1 (MD 0.04 L higher, 95% CI 0.34 
lower to 0.42 higher, low certainty), 6MWD (MD 14 meters higher, 95% CI 70.42 
lower to 98.42 higher, low certainty), sleep comfort measured by VAS scale (MD 1cm 
 
 
higher, 95% CI 28.42 lower to 30.42 higher; very low certainty) or PaO2 levels at 6 
weeks (MD 3.4 mmHg higher, 95% CI 2.39 lower to 9.19 higher, low certainty).  
 
Justification: The TF panel decided on a conditional recommendation for  
targeted reduction of PaCO2 in COPD patients with persistent hypercapnic 
respiratory failure.  Although the benefit was uncertain, this recommendation was 
driven by the minimal potential harms of targeted PaCO2 reduction [64,65] though it 
is recognized that this is unlikely to be achieved in all patients. While there is low 
certainty of evidence of benefit, the anticipated harms have not been clearly 
demonstrated, and as such the panel felt the overall balance favored the 
intervention. Setting NIV to target a reduction in PaCO2 may require more time 
spent in hospital [34], and therefore possibly increase costs and decrease feasibility 
of NIV, however, adherence was significantly better using this strategy. 
 
PICO Question 4: When using LTH-NIV in COPD patients, should we use fixed 
pressure modes as compared to adaptive or auto-titrating pressure modes? 
 
Recommendation: The ERS TF suggests using fixed pressure support mode as 
first-choice ventilator mode in patients with COPD using LTH-NIV (conditional 
recommendation, very low certainty evidence). 
 
 
 
Background: 
 In general, classical modes of LTH-NIV comprise both pressure-targeted and 
volume-targeted NIV. During pressure-targeted NIV the inspiratory pressure is set, 
while the delivered inspiratory volumes vary according to the impedance of the 
respiratory system and the patient‘s respiratory efforts. In contrast, during volume-
targeted NIV, a predetermined inspiratory volume is set, while inspiratory pressures 
are variable. Accordingly, the physiological advantage of volume-targeted NIV is the 
stability of tidal volume, while pressure-targeted NIV is advantageous regarding leak 
compensation when the inspiratory flow is increased in case of leak-related dropping 
pressure. Even though, physiological and short-term clinical studies indicate that 
pressure-targeted NIV is better tolerated due to less varying peak inspiratory 
pressures, both modes are reported to be comparably effective in providing non-
invasive ventilation, though the majority of studies have investigated heterogeneous 
patient cohorts and not exclusively patients with COPD [68-75]. Long-term studies 
comparing currently available ventilator modes do not exist, limiting the potential for 
strong conclusions. However, nearly all studies providing evidence for the use of 
LTH-NIV in COPD in PICO Q1 and PICO Q2 used pressure-targeted modes rather 
than volume-targeting modes of NIV, making pressure volume modes the de facto 
standard in LTH-NIV for COPD. 
 Recent developments seek to combine the advantages of volume- and 
pressure-targeted NIV, while avoiding their disadvantages [76]. In addition, there is a 
 
 
physiological rationale supporting the interest in continuously adapting ventilator 
parameters to fluctuating patient needs during the night and also over the long 
term. In addition, upper airway patency may vary with body position and sleep 
stage, especially during rapid eye movement (REM) sleep. Respiratory mechanics 
may also change as an individual‘s disease worsens over time. Ideally, LTH-NIV aims 
to deliver the adequate inspiratory pressure support to achieve targeted minute 
ventilation and sufficient expiratory pressure for complete stabilization of the upper 
airway. 
 The so called adaptive or auto-titrating modes have been designed to achieve 
these objectives even if applied with different software. There was also the hope that 
automatically identifying adequate settings for a given patient would allow 
implementation of NIV in non-specialized centers, thus favoring the widespread 
application of the technique. Conversely, there are certain complications and pitfalls 
related to these hybrid modes as depicted in detail elsewhere [76]. 
 
Evidence summary: 
 Six RCTs compared adaptive or auto-titrating pressure modes (eg. iVAPSTM, 
Resmed, Australia; AVAPSTM, Philips, US) to classical pressure support modes [77-82]. 
These studies were generally not blinded, and of short duration, prohibiting 
assessment of long-term outcomes such as mortality or hospitalizations. Six studies 
demonstrated that use adaptive or auto-titrating modes may result a small reduction 
 
 
in PaCO2 (MD 1.95 mmHg lower, 95% CI 4.29 mmHg lower to 0.40 mmHg higher, 
low certainty) and little to no difference in oxygenation (SMD -0.04, 95% CI -0.33 to 
0.26, low certainty) compared to conventional NIV. Adaptive or auto-titrating modes 
did not significantly improve HRQL using the SGRQ or the SRI (SMD 0.28, 95% CI -
0.66 to 0.10 SD, low certainty evidence), sleep quality measured using a variety of 
validated instruments (SMD - 0.14, 95% CI -0.53 to 0.26 SD, very low certainty), or 
exercise tolerance (SMD -0.1, 95% CI -0.51 to 0.30, low certainty compared to 
conventional fixed modes of NIV. 
 Adherence to NIV was equivalent when comparing adaptive or auto-titrating 
modes to conventional assist modes in five studies [77-81]. Regarding patient-
centered outcomes, no improvement in self-reported tolerance [78,80] or self-
reported comfort [77,78] was achieved with the newer modes. One study used a 
specific questionnaire to assess acceptability, but again no difference was 
demonstrated [82]. 
 
Justification 
 While the pooled analyses suggests a small potential benefit to adaptive or 
auto-titrating modes in PaCO2 reduction, and acceptable adherence, our 
recommendation is conditional for fixed modes owing to substantial uncertainty of 
the effects of adaptive or auto-titrating modes, and the heterogeneity across studies 
for algorithms, brands of devices and lack of detailed information regarding the way 
 
 
adaptive modes function. Moreover, there is uncertain risk of harm with 
adaptive/auto-titrating modes when there is severe air leak, a common clinical 
scenario, as adaptive modes require the ventilator to accurately measure/estimate 
tidal volumes [76]. This raises safety concerns, as inappropriate low volumes could 
be delivered in this situation, resulting in hypoventilation. The short follow-up of the 
available trials means there is little data on this potentially serious risk. Furthermore, 
there may be substantial additional cost to patients to upgrade to a machine 
equipped with these newer ventilatory modes if a patient is already using an older 
ventilator; however for patients starting with new devices the costs may be similar. 
 
Narrative Questions 
1. Do other factors impact the effectiveness of LTH-NIV in COPD? 
i. Patient related factors 
Age and comorbidities 
 The impact of age of a patient on outcome of LTH-NIV has not been 
evaluated. Previous RCTs excluded patients above 75 or 80 years old [31,38,44], 
more recently studies have not made age exclusion criteria, however, the elderly 
consisted of a very small proportion of the eligible subjects and the average age 
was mid-sixties [36,61,62]. Köhnlein et al. excluded patients with ―impaired general 
condition that could preclude regular follow-up visits‖ when evaluating survival 
benefit in stable COPD patients [36]. Borel et al., [83] in multivariate analysis of 
 
 
prospective, observational, survey (213 subjects, oldest age patient 76 years old) 
showed that older age is independently associated with poorer prognosis. Age itself 
cannot be considered an exclusion criterion. However, associated mental and/or 
physical disability and a lack of sufficient help of care-givers may significantly impair 
the efficacy of LTH-NIV. This issue should be addressed by the providers. 
 All but one RCT [61] excluded subjects with comorbidities such as: 
malignancy, severe heart failure, obstructive sleep apnea syndrome (OSAS), obesity, 
unstable angina [31,36,38,44, 48, 60, 62, 63]. As a result, the studied population was 
very homogenous, pure COPD, so called ―respiratory COPD‖ [84]. It is, therefore, 
difficult to answer whether the coexistence of the main COPD comorbidities has any 
impact on efficacy of LTH-NIV. However, the pathophysiological effect of airway 
positive pressure can provide additional positive outcomes in COPD patients with 
comorbidities, specifically, patients with pulmonary congestion or central apnea due 
to heart failure, hypoventilation in obese patients and OSAS. Borel et al. 
demonstrated better prognosis in obese subjects versus non-obese, moreover, the 
effect was independent on coexisting OSAS [83]. There was no benefit of the use of 
LTH-NIV in COPD patients with heart failure, however, it is worthy noticing that in 
the cohort of Borel at al. the proportion of subjects with heart failure; and 
hypertension was higher in the obese group with better prognosis than in the non-
obese group with worse outcomes [83]. 
 
 
 Cachexia is a frequent comorbidity in COPD and is associated with respiratory 
muscle atrophy-induced dysfunction [84]. Borel et al. found that lower body mass 
index (BMI) is independently associated with poorer prognosis [83]. The majority of 
RCTs average BMI was about 25 kg/m2 and subjects with BMI <19 kg/m2 practically 
were not enrolled. However, two RCTs on LTH-NIV after acute exacerbation, which 
enrolled subject with relatively low BMI 19 kg/m2 [60] and 21 kg/m2 [62], 
demonstrated significant prolongation of the time to readmission due to acute 
exacerbation. Finally, a previous study has demonstrated weight gain following NIV 
commencement, and this was particularly true for cachectic patients [85]. This 
suggests that cachectic COPD patients who usually suffer from severe dyspnea and 
weakness of the respiratory muscles may benefit from LTH-NIV . 
 In summary, comorbidities are not contraindications to LTH-NIV. Obese 
patients and patients with overlap syndrome (COPD+OSAS) make up the subgroup, 
which may benefit the most from LTH-NIV V. The initiation of LTH-NIV in patients 
with advanced COPD requires a high amount of motivation and cooperation and it 
is necessary to allow the patient sufficient time to adapt to NIV, especially when 
high inspiratory pressures are used [2]. 
 
Adherence   
 Adherence to therapy has a key role in the efficacy of LTH-NIV. However, 
there is no clear picture of the relationship between the number of hours per night 
 
 
use and the outcomes [38]. Mean compliance in RCTs which showed survival 
benefits of LTH-NIV were 4.5 [31] and about 6h/d [36], respectively. However, 
McEvoy et al. found the survival advantage was found to be better in the per-
protocol analysis (subjects with compliance > 4h/d, 60% of all) than in intention to 
treat analysis [31]. Conversely, Struik et al., found no correlation between number of 
hours of NIV per night and decrease in PaCO2 [61]. One uncontrolled trial 
demonstrated that adherence higher than 5 h/d improves survival in obese, but not 
non-obese COPD patients [83]. Interestingly, authors found high adherence over 9 
h/d was a marker of worse prognosis. One explanation is increased dependence on 
NIV is due to the worsening of the patient status. A minimum use of 5 hours per 
night was found to be needed to reach significant change in PaCO2 after three 
months of treatment in the meta-analysis using individual patient‘s data of all 
studies on LTH-NIV [7]. In conclusion, 5 hours of NIV per day would be a reasonable 
target however if patients do not achieve this, they may still receive clinical benefit.  
 
ii. Equipment related factors 
 Many technical details with home ventilators, masks, tubes and humidification 
can decrease tolerance, efficacy and produce secondary effects, affecting adherence 
to the treatment [1,86]. NIV can be delivered at home for COPD patients through 
nasal, oronasal, or full face mask. Although nasal masks offer greater patient 
comfort, they often have the problem of oral leaks especially during sleep, which in 
 
 
turn influence alveolar ventilation and sleep quality [1]. Currently, prescribers in 
Europe reported using oronasal masks more often as alveolar ventilation is much 
better with these than nasal masks, especially when high IPAP levels are used 
[27,87,88]. Full-face masks can serve as a supplement or an alternative to existing 
ventilation masks in the event of problems with pressure ulcers. Patients with 
frequent cough or abundant secretions either chronically or during an exacerbation 
usually do not tolerate oronasal masks and may use a nasal mask temporarily. There 
is no evidence that a particular interface guarantees greater benefit from LTH-NIV, 
so the choice should be carefully tailored to the patient choice.  
 Home ventilators can be used with a single circuit ventilation system with 
vented masks. The advantage of single circuits is their lower weight compared to 
double circuit systems and simpler handling, which is particularly important at home.  
 Circuits with expiratory valves can be also used. The expiration valve is located 
within the tubing circuit or in the ventilator. In an experimental study, the use of 
active valve circuits was associated with more efficient PaCO2 reduction when 
compared to leak port circuits [90], but it remains unclear how this is translated in 
clinical long-term application. 
 Ventilators without battery will be used when NIV is used for less time per 24 
hours. If the patient uses it for a longer duration (approximately12h / day depending 
on individual circumstances) a ventilator with internal battery should be considered. 
 
 
However, upgrading to a device with an internal battery does incur a significantly 
greater cost and this added burden may be not be feasible across a range of health 
systems with lower income economies. As a matter of the fact, the ventilator-
dependence threshold for transitioning to a device with an internal battery may be 
variable among the different countries [57]. 
 Active humidification is sometimes suggested for NIV [91] as it may improve 
adherence and comfort, but there is not clear consensus on whether or not 
additional heat and humidity are always necessary when the upper airway is not by-
passed, such as in NIV. Thus, it could be added if mucosal dryness becomes an 
issue. Two systems, active humidification through a heated humidifier (HH) and 
passive humidification through a heat and moisture exchanger (HME), are available 
for warming and humidifying gases. Use of an HME is not beneficial in patients on 
NIV with intentional leaks, as the patient does not exhale enough tidal volume to 
replenish heat and moisture to adequately condition the inspired gas. HME may add 
additional work of breathing and use of an HME increases dead space and PaCO2 
and may increase ventilatory requirements [92]. With HH and intentional leaks, 
aerosolize contaminated condensate may increase the risk for infection.  
 
  
 
 
iii. Additional therapies 
Supplemental oxygenation (LTOT+NIV) 
 Usually CRF in the course of COPD starts with hypoxemia and the first 
modality of treatment is LTOT, which improves survival [93]. The aim of oxygen 
therapy when added to LTH-NIV is to maintain the adequate oxygenation if this is 
not achieved by the correction of hypoventilation. The clinician needs to be aware 
that dose of oxygen which maintains oxygen saturation when awake can be 
insufficient during sleep with NIV.  
 
Pulmonary rehabilitation 
 Pulmonary rehabilitation (PR) is a cost-effective treatment for patients with 
COPD with the associated benefits of improved HRQL and increased exercise 
capacity [94-96]. Studies showed an increase in exercise tolerance with the addition 
of NIV whilst exercising [97-101]. Unfortunately, according to recent systematic 
reviews and British Thoracic Society (BTS) guidelines the benefits from using NIV 
during exercise training as add-on treatment to PR in patients with COPD were 
unclear, probably because of insufficient pressures applied [102-105].  
 Conversely, the addition of nocturnal LTH-NIV to daytime PR in COPD stable 
patients is likely to give more benefits. Garrod and co-workers [43] performed the 
first study evaluating nocturnal NIV+PR to PR alone non hypercapnic or hypoxic 
patients. They showed arterial blood gas (ABG) values improved in the NIV+PR 
 
 
group they also had a greater improvement in exercise tolerance and HRQL than PR 
alone. Duiverman et al. [106] compared PR to PR+NIV over 2 years in hypercapnic 
severe COPD in a RCT. PR+NIV improved HRQL, mood, dyspnea, ABG‘s, exercise 
tolerance and prevented as rapid decline of lung function. However, exacerbation 
frequency and mortality were not significantly different between groups. Coquart et 
al. [107] found home based PR in patients with NIV is feasible. They compared PR in 
patients on nocturnal CPAP, nocturnal NIV, LTOT or no additional equipment. They 
showed that the NIV group significantly increased walking distance when compared 
to the other conditions. Marquez-Martin and co-workers [50] performed a RCT over 
12 weeks comparing groups allocated to eitherPR, NIV and PR+NIV. Patients 
reportedly received 6-8 hours per night of NIV. There were improvements in exercise 
capacity for the PR and PR+NIV groups but not the NIV group alone. There were 
improvements in ABG‘s for the NIV and NIV+PR groups and the improvement were 
greater in the NIV+PR group.  
 There is a lack of data on enhancing of LTH-NIV by PR; however, the addition 
of PR to nocturnal NIV in COPD may have potential benefits of increasing exercise 
capacity and HRQL. 
 
Strategies to manage bronchopulmonary secretions 
 Consideration may be given to the use of airway clearance techniques for 
patients with COPD in both acute and stable disease, however current studies 
 
 
suggest that the benefits achieved may be small [108]. Airway clearance techniques 
in COPD patients may decrease hospitalizations [109]. It is logical that being free of 
secretions would help with adherence to NIV as there would be less coughing which 
can be a barrier to the use of ventilatory support. Moreover, being secretion free 
reduces the resistance of airways, and consequently improves ventilation, which may 
also contribute to improvements in ABG‘s. Mechanical insufflation-exsufflation 
devices are used in patients with NIV. There is no evidence that these devices 
increase cough effectiveness in patients with COPD [110], unless they have 
respiratory muscle weakness. However, no studies have compared LTH-NIV versus 
LTH-NIV and airway clearance techniques in patients with COPD. 
 Mucolytics are potentially useful for the management of COPD in patients 
that have tenacious secretions. A Cochrane review [111] and meta-analysis [112] 
found that mucolytic therapy led to an increase possibility of being exacerbation 
free compared to placebo. However, due to much heterogeneity between the 
studies, these data should be interpreted with caution. More recently, a European 
Respiratory Society/American Thoracic Society guideline [113] recommends an oral 
mucolytic in patients with moderate to severe airflow obstruction and exacerbations 
despite optimal inhaled therapy. No studies have compared LTH-NIV versus LTH-NIV 
and mucolytics in patients with COPD. However, it would seem reasonable to treat 
patients who complain of secretion retention to prevent secretions being a barrier to 
LTH-NIV in COPD. 
 
 
 
2. How can clinicians monitor and follow-up patients during LTH-NIV? 
 The recommendation of using high inspiratory pressure levels in COPD 
receiving LTH-NIV is to achieve a substantial decrease in PaCO2. The key thing is to 
document a reduction in PaCO2 during NIV. More sophisticated monitoring should 
be reserved for cases when expected results with NIV are not achieved. In a recent 
preliminary study, pressure titration with simplified methods in a cohort of COPD-
OSAS overlap patients achieved similar clinical effectiveness in terms of change in 3-
month daytime PaCO2, HRQL and sleep quality compared to polysomnography-
based pressure titration [114]. 
 The American Sleep Association recommends for the follow-up the 
assessment of clinical symptoms and an analysis of oxygenation and PaCO2 values 
during wakefulness and quiet breathing [115]. The outpatient control, with 
associated cost savings is possible following a strict protocol based on symptoms, 
ABG assessment, and simple monitoring tools [116]. Clinical evaluation should be 
focused on symptoms of nocturnal hypoventilation and discomfort with the device 
[1].  
 Nocturnal gas exchange monitoring (continuous oxygen saturation and 
transcutaneous PCO2 (PtcCO2) measure) is common in clinical practice [1,61,62, 
117,118]. Since home-ventilated COPD patients often receive oxygen therapy with 
NIV negating the usefulness of oxygen saturation with pulse oximetry (SpO2) 
 
 
monitoring for detecting nocturnal hypoventilation. On the other hand, isolated 
values of daytime PaCO2 cannot rule out nocturnal hypoventilation, particularly in 
neuromuscular patients [119]. Nocturnal monitoring with PtcCO2 allows detecting 
nocturnal hypoventilation as there is minimal drift with modern devices [120]. In the 
recent HOT-HMV trial, there was a statistically significant reduction in nocturnal 
PtcCO2 levels on the night after initiation of noninvasive ventilation, which reportedly 
persisted to 12 months [62]. Finally, uncontrolled nocturnal hypoventilation seems to 
be related to increased risk of exacerbations and pulmonary hypertension [121]. End 
tidal carbon dioxide monitoring should never be used to approximate PaCO2 in 
patients with COPD during spontaneous breathing or NIV and is even less reliable in 
patients with invasive ventilation [122,123] 
 In recent years, improvements introduced by manufacturers in their models 
have led these devices to act both as ventilators and monitors. Data stored in the 
internal memory of such devices provide information about compliance, pattern of 
usage, respiratory rate, percentage of patient triggered breaths, leakage, and in 
some models, "breath to breath" display of pressure and flow time waveforms. 
Changes in some of the recorded parameters (eg. respiratory rate and patient 
triggered breaths) in the preceding days have been able to predict exacerbations in 
COPD patients receiving LTH-NIV [124]. In addition, some manufacturers have 
developed algorithms for automatic estimation of leaks and residual upper airway 
obstructions (UAO). Residual UAO is common in patients undergoing nocturnal NIV 
 
 
[125] and their lack of correction has been associated with increased mortality in 
amyotrophic lateral sclerosis patients [126]. UAO estimation by algorithms showed 
reasonable accuracy compared with PSG and manual scoring [127]. For the near 
future, technical advances in this field would allow to integrate them in telemedicine 
programs, although specific studies in COPD home ventilated patients are lacking. 
Interestingly, telemonitoring added to standard care did not alter time to next acute 
hospital admission, increase hospital admissions and home visits overall, and did not 
improve HRQL in a cohort of patients with CRF in a randomized crossover trial [128]. 
 Finally, patient-ventilator asynchrony (PVA) may occur during the night. 
Theoretically, these events can compromise the effectiveness of the ventilation, but 
their importance remains unknown, mainly for two reasons: the absence of validated 
guidelines containing the classification of PVA and the scoring procedure in home 
mechanically ventilated patients, and the limited number of studies addressing this 
issue, with conflicting results. In a small cohort of COPD patients receiving NIV at 
home, the adjustments directed towards the decrease in PVA improved morning 
breathlessness [129]. However, in another study PVA has been demonstrated to have 
no impact on overnight gas exchange during set-up of LTH-NIV [130]. 
 In summary, monitoring of COPD patients on LTH-NIV is focused on the 
control of nocturnal hypoventilation with overnight CO2 monitoring. Further research 
on patient ventilator interactions is needed. 
 
 
 
Conclusion 
 The TF developed actionable recommendations for 4 PICO questions, and 
narrative summaries for 2 other questions. These recommendations are accompanied 
by discussions of implementation considerations and suggestions for future research 
(Table 3).  
 
 This clinical practice guideline was produced using comprehensive GRADE 
methodology. Each PICO question was informed by a comprehensive systematic 
review and certainty of evidence evaluated in order to guide discussion. 
Recommendation generation was performed using the Evidence-to-Decision process 
to ensure all relevant considerations were incorporated. One limitation in this 
guideline is the lack of patient input for PICO questions and outcome 
prioritization. Despite this, the TF panel specifically tried to focus and prioritize 
patient-centered outcomes from available literature data, such as dyspnea, quality of 
sleep and HRQL and use these outcomes to drive recommendation generation. 
Given the limitations of the evidence, decisions about implementing LTH-NIV in 
COPD for many patients will depend upon resource constraints— whether or not 
NIV is funded by insurers, whether acclimation takes place in hospital or a sleep lab, 
etc. The feasibility of these recommendations my thus vary across health systems. 
 
Our recommendations, based on the best available evidence, can guide the 
 
 
management of  chronic hypercapnic respiratory failure in COPD patients aimed at 
improving patient outcomes. However, they should be interpreted as conditional 
recommendations and should be implemented based on patient-related factors, 
including individual values and preferences. Adequately designed and executed RCTs 
that properly measure and report all patient-important outcomes are still 
needed. We anticipate significant progress in the field of LTH-NIV  in the 
forthcoming years and as such these recommendations will require re-evaluation in 
the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
1. Windisch W, Geiseler J, Simon K, Walterspacher S, Dreher M, Guideline 
Commission. German national guideline for treating chronic respiratory failure 
with invasive and non-invasive ventilation: revised edition 2017–part 1. 
Respiration 2018;96(1):66-97. 
2. Windisch W, Geiseler J, Simon K, Walterspacher S, Dreher M, Guideline 
Commission. German national guideline for treating chronic respiratory failure 
with invasive and non-invasive ventilation–revised edition 2017: part 2. 
Respiration 2018;96(2):171-203. 
3. Rochwerg B, L Brochard, Elliott MW, Hess D, Hill NS, Nava S, Navalesi P, 
Antonelli M, Brozek J, Conti G, Ferrer M, Guntupalli K, Jaber S, Keenan S, 
Mancebo J, Mehta S, Raoof S. Official ERS/ATS clinical practice guidelines: 
noninvasive ventilaiton for acute respiratory failure. Eur Respir J 2017; 
50:1602426. 
4. Schwarz SB, Magnet FS, Windisch W. Why high-intensity NPPV is favourable 
to low-intensity NPPV: clinical and physiological reasons. COPD 2017; 
14(4):389-95. 
5. Masefield S, Vitacca M, Dreher M, Kampelmacher M, Escarrabill J, Paneroni M, 
Powell P, Ambrosino N. Attitudes and preferences of home mechanical 
ventilation users from four European countries: an ERS/ELF survey. ERJ Open 
Res 2017;3:00015-2017. 
 
 
6. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, Alderson P, Glasziou 
P, Falck-Ytter Y, Schünemann HJ. GRADE guidelines: 2. Framing the question 
and deciding on important outcomes. J Clin Epidemiol 2011 Apr 1;64(4):395-
400. 
7. Struik FM, Lacasse Y, Goldstein RS, Kerstjens HA, Wijkstra PJ. Nocturnal 
noninvasive positive pressure ventilation in stable COPD: a systematic review 
and individual patient data meta-analysis. Respiratory Medicine. 2014 Feb 
1;108(2):329-37. 
8. Shen G, Shen X, Shen J, He L, Xu Y, Liu R. Effects of long-term non-invasive 
ventilation in stable chronic obstructive pulmonary disease: a systematic 
review of 16 randomized controlled trials. Int J Clin Exp Med. 2016 Jan 
1;9(2):468-84. 
9. Dretzke J, Moore D, Dave C, Mukherjee R, Price MJ, Bayliss S, Wu X, Jordan 
RE, Turner AM. The effect of domiciliary noninvasive ventilation on clinical 
outcomes in stable and recently hospitalized patients with COPD: a systematic 
review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2016;11:2269. 
10. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, 
Akl EA, Djulbegovic B, Falck-Ytter Y, Norris SL. GRADE guidelines: 4. Rating the 
quality of evidence—study limitations (risk of bias). J Clin Epidemiol 2011 Apr 
1;64(4):407-15. 
11. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-
 
 
Coello P, Glasziou P, Jaeschke R, Akl EA, Norris S. GRADE guidelines: 7. Rating 
the quality of evidence—inconsistency. J Clin Epidemiol 2011 Dec 
1;64(12):1294-302. 
12. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-
Coello P, Falck-Ytter Y, Jaeschke R, Vist G, Akl EA. GRADE guidelines: 8. Rating 
the quality of evidence—indirectness. J Clin Epidemiol 2011 Dec 
1;64(12):1303-10. 
13. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux 
PJ, Montori VM, Freyschuss B, Vist G, Jaeschke R. GRADE guidelines 6. Rating 
the quality of evidence—imprecision. J Clin Epidemiol 2011 Dec 1;64(12):1283-
93. 
14. GRADE Working Group. Guideline Development Tool. 2014. 
https://gdt.gradepro.org/app/handbook/handbook.html Date last accessed: 
September 20, 2018.  
15. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli 
M, Treweek S, Mustafa RA, Vandvik PO, Meerpohl J, Guyatt GH, Schünemann 
HJ, GRADE working group. GRADE Evidence to Decision (EtD) frameworks: a 
systematic and transparent approach to making well informed healthcare 
choices. 2: Clinical practice guidelines. BMJ 2016; 353: i2089.  
16. Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going 
from evidence to recommendation – determinants of a recommendation‘s 
 
 
direction and strength. J Clin Epidemiol 2013; 66: 726–735 
17.  Guyatt GH, Oxman AD, Kunz R, Falck- Ytter Y, Vist GE, Liberati A et al (2008) 
Going from evidence to recommendations. BMJ 336(7652):1049–1051 
18. Rochwerg B, Alhazzani W, Jaeschke R. Clinical meaning of the GRADE rules. 
Intensive Care Med. 2014 Jun 1;40(6):877-9. 
19. Ambrosino N, Simonds A. The clinical management in extremely severe COPD. 
Respiratory medicine. 2007 Aug 1;101(8):1613-24. 
20. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, 
Connell C, Jemal A, Lee TA, Miravitlles M, Aldington S. Epidemiology and costs 
of chronic obstructive pulmonary disease. European Respiratory Journal. 2006 
Jan 1;27(1):188-207. 
21. Ahmadi Z, Bornefalk-Hermansson A, Franklin KA, Midgren B, Ekström MP. 
Hypo-and hypercapnia predict mortality in oxygen-dependent chronic 
obstructive pulmonary disease: a population-based prospective study. Respir 
Res. 2014 Mar 13;15:30. doi: 10.1186/1465-9921-15-30. 
22. Saraiva C, Abreu T, Neves D, Rodrigues F. Mortality Predictive Factors in 
Subjects With COPD After a Pulmonary Rehabilitation Program: A 3-Year 
Study. Respir Care. 2016 Sep;61(9):1179-85. doi: 10.4187/respcare.04477. 
23. Connors AF jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, 
Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute 
exacerbation of severe chronic obstructive lung disease. The SUPPORT 
 
 
Investigators (Study to understand prognoses and preferences for outcomes 
and risks of treatments). Am J Respir Crit Care Med 1996 Oct; 154(4 Pt 1); 
959-67. 
24. Costello R, Deegan P, Fitzpatrick M, McNicholas WT. Reversible hypercapnia in 
chronic obstructive pulmonary disease: a distinct pattern of respiratory failure 
with a favorable prognosis. Am J Med 1997 Mar; 10283):239-44. 
25. Foucher P, Baudouin N, Merati M, Pitard A, Bonniaud P, Reybet-Degat O, 
Jeannin L. Relative survival analysis of 252 patients with COPD receiving long-
term oxygen therapy. Chest. 1998 Jun;113(6):1580-7. 
26. Windisch W, Storre JH, Köhnlein T. Nocturnal non-invasive positive pressure 
ventilation for COPD. Expert Rev Respir Med. 2015 Jun;9(3):295-308. doi 
10.1586/17476348.2015.1035260. 
27. Crimi C, Noto A, Princi P, Cuvelier A, Masa JF, Simonds A, Elliott MW, Wijkstra 
P, Windisch W, Nava S. Domiciliary Non-invasive Ventilation in COPD: An 
International Survey of Indications and Practices. COPD. 2016 Aug;13(4):483-
90. doi: 10.3109/15412555.2015.1108960. 
28. Nava S, Fanfulla F, Frigerio P, Navalesi P. Physiologic evaluation of 4 weeks of 
nocturnal nasal positive pressure ventilation in stable hypercapnic patients 
with chronic obstructive pulmonary disease. Respiration. 2001;68(6):573-83. 
29. Turkington PM, Elliott MW. Rationale for the use of non-invasive ventilation in 
chronic ventilatory failure. Thorax. 2000 May;55(5):417-23. 
 
 
30. Windisch W, Dreher M, Storre JH, Sorichter S. Nocturnal non-invasive positive 
pressure ventilation: physiological effects on spontaneous breathing. Respir 
Physiol Neurobiol. 2006 Feb 28;150(2-3):251-60. 
31. McEvoy RD, Pierce RJ, Hillman D, Esterman A, Ellis EE, Catcheside PG, 
O'Donoghue FJ, Barnes DJ, Grunstein RR; Australian trial of non-invasive 
Ventilation in Chronic Airflow Limitation (AVCAL) Study Group. Nocturnal non-
invasive nasal ventilation in stable hypercapnic COPD: a randomised 
controlled trial. Thorax. 2009 Jul;64(7):561-6 
32. Windisch W, Vogel M, Sorichter S, Hennings E, Bremer H, Hamm H, Matthys 
H, Virchow JC Jr. Normocapnia during nIPPV in chronic hypercapnic COPD 
reduces subsequent spontaneous PaCO2. Respir Med. 2002 Aug;96(8):572-9. 
33. Windisch W, Kostić S, Dreher M, Virchow JC Jr, Sorichter S. Outcome of 
patients with stable COPD receiving controlled noninvasive positive pressure 
ventilation aimed at a maximal reduction of Pa(CO2). Chest. 2005 
Aug;128(2):657-62. 
34. Dreher M, Storre JH, Schmoor C, Windisch W. High-intensity versus low-
intensity non-invasive ventilation in patients with stable hypercapnic COPD:  a 
randomised crossover trial. Thorax. 2010 Apr;65(4):303-8. 
35. Windisch W, Haenel M, Storre JH, Dreher M. High-intensity non-invasive 
positive pressure ventilation for stable hypercapnic COPD. Int J Med Sci 2009; 
6:72-76. 
 
 
36. Köhnlein T, Windisch W, Köhler D, Drabik A, Geiseler J,Hartl S, et al. Non-
invasive positive pressure ventilation for the treatment of severe stable 
chronic obstructive pulmonary disease: a prospective, multicentre, randomised, 
controlled clinical trial. Lancet Respir Med 2014; 2(9):698–705. 
37. Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, Vestbo J, Feenstra 
TL. Case fatality of COPD exacerbations: a meta-analysis and statistical 
modelling approach. Eur Respir J 2011 Mar;37(3):508-15. 
38. Clini E, Sturani C, Rossi A, Viaggi S, Corrado A, Donner CF, Ambrosino N; 
Rehabilitation and Chronic Care Study Group, Italian Association of Hospital 
Pulmonologists (AIPO), The Italian multicentre study on noninvasive ventilation 
in chronic obstructive pulmonary disease patients. Eur Respir J  2002 
Sep;20(3):529-38 
39. Duiverman ML, Wempe JB, Bladder G, Jansen DF, Kerstjens HA, Zijlstra JG, 
Wijkstra PJ. Nocturnal non-invasive ventilation in addition to rehabilitation in 
hypercapnic patients with COPD. Thorax 2008 Dec;63(12):1052-7. 
40. Strumpf DA, Millman RP, Carlisle CC, Grattan LM, Ryan SM, Erickson AD, Hill 
NS. Nocturnal positive -pressure ventilation via nasal mask in patients with 
severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1991 Dec; 
144(6):1234-9. 
41. Gay PC, Hubmayr RD, Stroetz RW. Efficacy of nocturnal nasal ventilation in 
stable, severe chronic obstructive pulmonary disease durind a 3-month 
 
 
controlled trial. Mayo Clin Proc 1996 jun; 71(6):533-42. 
42. Kaminski D, Sliwinski P, Bielen P, Zielinski J. Noninvasive positive pressure 
ventilaiton in COPD patients with hypercapnic respiratory failure. Pneumonol 
Alergol Pol 1999; 67(1-2):45-52. 
43. Garrod R, Mikelsons C, Paul EA, Wedzicha JA. Randomized controlled trial of 
domiciliary noninvasive positive pressure ventilaiton and physical training in 
severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000 
Oct;162(4 Pt 1):1335-41 
44. Casanova C, Celli BR, Tost L, Soriano E, Abreu J, Velasco V, Santolaria F. Long-
term controlled trial of nocturnal nasal positive pressure ventilation in patients 
with severe COPD. Chest 2000 Dec; 118(6):1582-90 
45. Sin DD, Wong E, Mayers I, Lien DC, Feeny D, Cheung H, Gan WQ, Man SF. 
Effects of nocturnal noninvasive mechanical ventilation on heart rate variability 
of patients with advanced COPD. Chest 2007 Jan; 131(1):156-63. 
46. Bhatt SP, Peterson MW, Wilson JS, Durairaj L. Noninvasive positive pressure 
ventilation in subjects with stable COPD:a randomized trial. Int J Chron 
Obstruct Pulmon Dis 2013; 8:581-9. 
47. Shebl RE, Abderaboh MM. Bi-level positive airway pressure ventilation for 
patients with stable chronic obstructive pulmonary disease. Egyptian Journal 
of Chest Diseases and Tuberculosis 2015; 64(2):395-398. 
48. Zhou L, Li X, Guan L, Chen J, Guo B, Wu W, Huo Y, Zhou Z, Liang Z, Zhou Y, 
 
 
Tan J, Chen X, Song Y, Chen R. Home noninvasive positive pressure ventilation 
with built in software in stable hypercapnic COPD: a short-term prospective, 
multicenter, randomized, controlled trial. Int J Chron Obstruct Pulmon Dis 
2017 Apr; 12:1279-1286. 
49. Chiang LL, Liu CY, Ho SC, Sheng TF, Yu CT, Lin HC, Kuo HP. Efficacy of 
nocturnal nasal positive pressure ventilation in hypercapnic patients with 
severe obstructive lung diseases. Chang Gung Med J 2004 Feb; 27(2):98-106 
50. Marquez-Martin E, Ruiz FO, RAmos PC, Lopez-Campos JL, Azcona BV, Cortes 
EB. Randomized trial of non-invasive ventilation combined with exercise 
training in patients with chronic hypercapni failure due to chronic obstructive 
pulmonary disease. Respir Med 2014 Dec; 108(12):1741-51. 
51. Schneeberger T, Stegemann A, Schoenheit-Kenn U, Jarosch I, Gloeckl R, 
Kohnlein T, Kenn K. Nocturnal non invasive ventilation as an adjunct for 
pulmonary rehabilitation in patients with very severe COPS- a randomized 
controlled trial. Am J Respir Crit Care Med 2017;195:A2851. 
52. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. 
Minimal clinically important differences in pharmacological trials. Am J Respir 
Crit Care Med 2014; 189(3):250-255. 
53. Nava S, Navalesi P, Gregoretti C. Interfaces and humidification for noninvasive 
mechanical ventilation. Respir Care. 2009 Jan;54(1):71-84.  
54. Brill AK. How to avoid interface problems in acute noninvasive ventilation. 
 
 
Breathe. 2014 Sep 1;10(3):230-42. 
55. Tuggey JM, Plant PK, Elliott MW. Domiciliary non-invasive ventilation for 
recurrent acidotic exacerbations of COPD: an economic analysis. Thorax. 2003 
Oct;58(10):867-71. 
56.  Lujan M, Lalmolda C, Ergan B. Basic concepts for tidal volume and leakage 
estimation in non-invasive ventilation. Turk Thorac J. 2019; 20(2): 140-4. 
57. Skoczyń ski S, Scala R, Navalesi P. Survey on accessibility and real-life 
application of noninvasive ventilation. ERJ Open Res. 2018 Nov 2;4(4). 
58. Lun CT, Tsui MS, Cheng SL, Chan VL, Leung WS, Cheung AP, Chu CM. 
Differences in baseline factors and survival between normocapnia, 
compensated respiratory acidosis and decompensated respiratory acidosis in 
COPD exacerbation: A pilot study. Respirology. 2016 Jan;21(1):128-36. 
59. Xiang PC, Zhang X, Yang JN, Zhang EM, Guo WA, Ju LX, Zhang S, Zhu WJ, Lei 
T, Cheng XS. [The efficacy and safety of long term home noninvasive positive 
pressure ventilation in patients with stable severe chronic obstructive 
pulmonary disease]. Zhonghua Jie He He Hu Xi Za Zhi. 2007 Oct;30(10):746-
50. 
60. Cheung AP, Chan VL, Liong JT, Lam JY, Leung WS, Lin A, Chu CM. A pilot trial 
of non-invasive home ventilation after acidotic respiratory failure in chronic 
obstructive pulmonary disease. Int J Tuberc Lung Dis. 2010 May;14(5):642-9. 
61. Struik FM, Sprooten RT, Kerstjens HA, Bladder G, Zijnen M, Asin J, Cobben NA, 
 
 
Vonk JM, Wijkstra PJ. Nocturnal non-invasive ventilation in COPD patients with 
prolonged hypercapnia after ventilatory support for acute respiratory failure: a 
randomised, controlled, parallel-group study. Thorax. 2014 Sep;69(9):826-34. 
62. Murphy PB, Rehal S, Arbane G, Bourke S, Calverley PMA, Crook AM, Dowson 
L, Duffy N, Gibson GJ, Hughes PD, Hurst JR, Lewis KE, Mukherjee R, Nickol A, 
Oscroft N, Patout M, Pepperell J, Smith I, Stradling JR, Wedzicha JA, Polkey 
MI, Elliott MW, Hart N. Effect of home noninvasive ventilation with oxygen 
therapy vs oxygen therapy alone on hospital readmission or death after an 
acute COPD exacerbation: a randomized clinical trial. JAMA. 2017 Jun 
6;317(21):2177-2186 
63. Funk GC, Breyer MK, Burghuber OC, Kink E, Kirchheiner K, Kohansal R, Schmidt 
I, Hartl S. Long-term non-invasive ventilation in COPD after acute-on-chronic 
respiratory failure. Respir Med. 2011 Mar;105(3):427-34 
64. Lukácsovits J, Carlucci A, Hill N, Ceriana P, Pisani L, Schreiber A, Pierucci P, 
Losonczy G, Nava S. Physiological changes during low- and high-intensity 
noninvasive ventilation. Eur Respir J. 2012 Apr;39(4):869-75. doi: 
10.1183/09031936.00056111. 
65. Duiverman ML, Maagh P, Magnet FS, Schmoor C, Arellano-Maric MP, Meissner 
A, Storre JH, Wijkstra PJ, Windisch W, Callegari J. Impact of High-Intensity-NIV 
on the heart in stable COPD: a randomised cross-over pilot study. Respir Res. 
2017 May 2;18(1):76. doi: 10.1186/s12931-017-0542-9. 
 
 
66. Dreher M, Ekkernkamp E, Walterspacher S, Walker D, Schmoor C, Storre JH, 
Windisch W. Noninvasive ventilation in COPD: impact of inspiratory pressure 
levels on sleep quality. Chest. 2011 Oct;140(4):939-945. 
67. Murphy PB, Brignall K, Moxham J, Polkey MI, Davidson AC, Hart N. High 
pressure versus high intensity noninvasive ventilation in stable hypercapnic 
chronic obstructive pulmonary disease: a randomized crossover trial. Int J 
Chron Obstruct Pulmon Dis. 2012;7:811-8. doi: 10.2147/COPD.S36151. 
68. Windisch W, Storre JH, Sorichter S, Virchow Jr JC. Comparison of volume- and 
pressure-limited NPPV at night: a prospective randomized cross-over trial. 
Respir Med 2005;99:52-9. 
69. Tuggey JM, Elliott MW. Randomised crossover study of pressure and volume 
non-invasive ventilation in chest wall deformity. Thorax 2005;60:859-64. 
70. Mehta S, McCool FD, Hill NS. Leak compensation in positive pressure 
ventilators: a lung model study. Eur Respir J 2001; 17:259–67. 
71. Meecham Jones DJ, Wedzicha JA. Comparison of pressure and volume preset 
nasal ventilator systems in stable chronic respiratory failure. Eur Respir J 
1993;6:1060–4. 
72. Elliott MW, Aquilina R, Green M, Moxham J, Simonds AK. A comparison of 
different modes of noninvasive ventilatory support: effects on ventilation and 
inspiratory muscle effort. Anaesthesia 1994;49:279–83. 
73. Schönhofer B, Sonneborn M, Haidl P, Bohrer H, Köhler D. Comparison of two 
 
 
different modes for noninvasive mechanical ventilation in chronic respiratory 
failure: volume versus pressure controlled device. Eur Respir J 1997;10: 184–91. 
74. Smith IE, Shneerson JM. Secondary failure of nasal intermittent positive 
pressure ventilation using the Monnal D: effects of changing ventilator. Thorax 
1997;52:89. 
75. Storre JH, Bohm P, Dreher M, Windisch W. Clinical impact of leak 
compensation during non-invasive ventilation. Respir Med 2009; 103:1477-
1483. 
76. Arellano-Maric MP, Gregoretti C, Duivermann M, Windisch W. Long-term 
volume-targeted pressure-controlled ventilation: sense or nonsense? Eur 
Respir J. 2017 Jun 22;49(6). pii: 1602193 
77. Crisafulli E, Manni G, Kidonias M, Trianni L, Clini EM. Subjective sleep quality 
during average volume assured pressure support (AVAPS) ventilation in 
patients with hypercapnic COPD: a physiological pilot study.Lung. 
2009;187(5):299-305. doi: 10.1007/s00408-009-9167-1.  
78. Oscroft NS, Ali M, Gulati A, Davies MG, Quinnell TG, Shneerson JM, Smith IE. 
A randomised crossover trial comparing volume assured and pressure preset 
noninvasive ventilation in stable hypercapnic COPD.COPD. 2010;7(6):398-403. 
doi: 10.3109/15412555.2010.528084.  
79. Oscroft NS, Chadwick R, Davies MG, Quinnell TG, Smith IE. Volume assured 
versus pressure preset non-invasive ventilation for compensated ventilatory 
 
 
failure in COPD. Respir Med. 2014 Oct;108(10):1508-15. doi: 
10.1016/j.rmed.2014.07.010  
80. Storre JH, Matrosovich E, Ekkernkamp E, Walker DJ, Schmoor C, Dreher M, 
Windisch W. Home mechanical ventilation for COPD: high-intensity versus 
target volume noninvasive ventilation. Respir Care. 2014;59(9):1389-97. doi: 
10.4187/respcare.02941  
81. Ekkernkamp E, Storre JH, Windisch W, Dreher M. Respiration. 2014;88(4):270-6. 
Impact of intelligent volume-assured pressure support on sleep quality in 
stable hypercapnic chronic obstructive pulmonary disease patients: a 
randomized, crossover study.doi: 10.1159/000364946. 
82. Nilius G, Katamadze N, Domanski U, Schroeder M, Franke KJ. Non-invasive 
ventilation with intelligent volume-assured pressure support versus pressure-
controlled ventilation: effects on the respiratory event rate and sleep quality in 
COPD with chronic hypercapnia. Int J Chron Obstruct Pulmon Dis. 
2017;12:1039-1045. doi: 10.2147/COPD.S126970. eCollection 2017. 
83. Borel JC, Pepin JL, Pison C, Vesin A, Gonzalez-Bermejo J, Court-Fortune I, 
Timsit JF. Long-term adherence with non-invasive ventilation improves 
prognosis in obese COPD patients. Respirology 2014; 19(6):857–865. 
84. Dudgeon D, Baracos VE. Physiological and functional failure in chronic 
obstructive pulmonary disease, congestive heart failure and cancer: a 
 
 
debilitating intersection of sarcopenia, cachexia and breathlessness. Curr Opin 
Support Palliat Care 2016; 10(3):236-41. 
85. Budweiser S, Heinemann F, Meyer K, Wild PJ, Pfeifer M. Weight gain in 
cachectic COPD patients receiving non-invasive positive pressure ventilation. 
Respir Care 2006; 51(2):126-132. 
86. Garcia-Aymerich J, Gómez FP, Benet M, Farrero E, Basagaña X, Gayete À, Paré 
C, Freixa X, Ferrer J, Ferrer A, Roca J, Gáldiz JB, Sauleda J, Monsó E, Gea J, 
Barberà JA, Agustí À, Antó JM; PAC-COPD Study Group. Identification and 
prospective validation of clinically relevant chronic obstructive pulmonary 
disease (COPD) subtypes. Thorax 2011 May;66(5):430-7.  
87. Arnal JM, Texereau J, Garnero A. Practical insight to monitor home NIV in 
COPD patients. COPD 2017 Aug; 14(4):401-410.  
88. Navalesi P, Fanfulla F, Frigerio P, Gregoretti C, Nava S. Physiologic evaluation 
of noninvasive mechancial ventilation delivered with the three types of masks 
in patients with chronic hypercapnic respiratory failure. Crit Care Med 2000; 
28(6):1785-1790. 
89. Callegari J, Magnet FS, Taubner S, Berger S, Schwarz SB, Windisch W, Strorre 
JH. Interfaces and ventilator settings for long-term noninvasive ventilation in 
COPD patients. Int J Chron Obstruct Pulmon Dis 2017 Jun 28; 12:1883-1889. 
 
 
90. Storre JH, Huttmann SE, Ekkernkamp E, Walterspacher S, Schmoor C, Dreher 
M, Windisch W. Oxygen supplementation in noninvasive home mechanical 
ventilation: The crucial roles of CO2 exhalation systems and leakages. Respir 
Care 2014; 59(1):113-120. 
91. American Association for Respiratory Care, Restrepo RD, Walsh 
BK.Humidification during invasive and noninvasive mechanical ventilation. 
Respir Care 2012 May; 57(5):782-8. 
92. Lellouche F, Maggiore SM; Deye N, Taille S, Pigeot J, Harf A, Brochard L. Effect 
of the humidification device on the work of breathing during noninvasive 
ventilation. Intensive Care Med 2002; 28(11):1582-1589. 
93. Hardinge M, Annandane J, Bourne S,Cooper B, Evans A, Freeman D, Green A, 
Hippolyte S, Knowles V, Mac Nee W, McDonnell L, Pye K, Suntharalingam J, 
Vora V, Wilkonson T; British Thoracic Society Home Oxygen Guideline 
Development Group; British Thoracic Society Standarts of Care Committee. 
British Thoracic Society guidelines for home oxygen use in adults. Thorax 
2015; 70:i1-i43. 
94. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic 
Society/European Respiratory Society statement: key concepts and advances 
in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188(8):e13-64. 
 
 
95. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary 
rehabilitation for chronic obstructive pulmonary disease. Cochrane Database 
Syst Rev 2015; (2):CD003793.  
96. Puhan MA, Gimeno-Sants E, Cates CJ, Troosters T.  Pulmonary rehabilitation 
following exacerbations of chronic obstructive pulmonary disease. Cochrane 
Database Syst Rev, 2016;  12:CD005305.  
97. Vitacca M, Kaymaz D, Lanini B, Vagheggini G, Ergün P, Gigliotti F, Ambrosino 
N, Paneroni M. Non-invasive ventilation during cycle exercise training in 
patients with chronic respiratory failure on long-term ventilatory support: A 
randomized controlled trial. Respirology 2018; 23(2):182-189. 
98. Costes F, Agresti A, Court-Fortune I, Roche F, Vergnon JM, Barthelemy JC. 
Noninvasive ventilation during exercise training improves exercise tolerance in 
patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 
2003; 23(4):307-13 
99. Keilty SE, Ponte J, Fleming TA, Moxham J. Effect of inspiratory pressure 
support on exercise tolerance and breathlessness in patients with severe 
stable chronic obstructive pulmonary disease. Thorax 1994; 49(10):990-4. 
100. Hawkins P, Johnson LC, Nikoletou D, Hamnegard CH, Sherwood R, 
Polkey MI, Moxham J. Proportional assist ventilation as an aid to exercise 
 
 
training in severe chronic obstructive pulmonary disease. Thorax 2002; 
57(10):853-9. 
101. Dreher M, Storre JH, Windisch W. Noninvasive ventilation during 
walking in patients with severe COPD: a randomised cross-over trial. Eur 
Respir J 2007; 29(5):930-6. 
102. Menadue C, Piper AJ, vant Hul AJ, Wong KK. Non-invasive ventilation 
during exercise training for people with chronic obstructive pulmonary 
disease. Cochrane Database Syst Rev 2014; (5):CD007714. 
103. Ricci C, Terzoni S, Gaeta M, Sorgente A, Destrebecq A, Gigliotti F. 
Physical training and noninvasive ventilation in COPD patients: a meta-
analysis. Respir Care 2014; 59(5):709-17. 
104. Camillo CA, Osadnik CR, van Remoortel H, et al. Effect of "add-on" 
interventions on exercise training in individuals with COPD: a systematic 
review. ERJ Open Res 2016; 2(1). 
105. Bolton CE, Bevan-Smith EF, Blakey JD, Crowe P, Elkin SL, Garrod R, 
Greening NJ, Heslop K, Hull JH, Man WD, Morgan MD, Proud D, Roberts CM, 
Sewell L, Singh SJ, Walker PP, Walmsley S; British Thoracic Society Pulmonary 
Rehabilitation Guideline Development Group; British Thoracic SocietyStandarts 
of Care Committee. British Thoracic Society guideline on pulmonary 
rehabilitation in adults. Thorax 2013; 68 Suppl 2:ii1-30 
 
 
106. Duiverman ML, Wempe JB, Bladder G, Vonk JM, Zijlstra JG, Kerstjens 
HA, Wijkstra PJ. Two-year home-based nocturnal noninvasive ventilation 
added to rehabilitation in chronic obstructive pulmonary disease patients: a 
randomized controlled trial. Respir Res 2011; 12:112. 
107. Coquart JB, Le Rouzic O, Racil G, Wallert B, Grosbois JM. Real-life 
feasibility and effectiveness of home-based pulmonary rehabilitation in 
chronic obstructive pulmonary disease requiring medical equipment. Int J 
Chron Obstruct Pulmon Dis 2017; 12:3549-3556. 
108. Osadnik CR, McDonald CF, Jones AP, Holland AE. Airway clearance 
techniques for chronic obstructive pulmonary disease. Cochrane Database Syst 
Rev. 2012(3): CD008328. 
109. Burudpakdee C, Seetasith A, Kauffman G, Carlin B, Coppolo D, Suggett 
J. A real-world study of 30-day exacerbation outcomes in chronic obstructive 
pulmonary disease (COPD) patients managed with Aerobika OPEP. Pulmonary 
Therapy, 2017; 3(1):163-171. 
110. Winck JC, Gonçalves MR, Lourenco C, Viana P, Almeida J, Bach JR. 
Effects of mechanical insufflation-exsufflation on respiratory parameters for 
patients with chronic airway secretion encumbrance. Chest, 2004; 126(3):774-
80. 
 
 
111. Poole P, Chong J, and Cates CJ. Mucolytic agents versus placebo for 
chronic bronchitis or chronic obstructive pulmonary disease. Cochrane 
Database Syst Rev 2015; (7):CD001287. 
112. Cazzola M, Rogliani P, Calzetta L, Hanania NA, Matera MG. Impact of 
mucolytic agents on COPD exacerbations: a pair-wise and network meta-
analysis. COPD, 2017. 14(5): p. 552-563. 
113. Wedzicha JA, Calverley PMA, Albert RK, Anzueto A, Criner GJ, Hurst JR, 
Miratvitlles M, Papi A, Rabe KF, Rigau D, Sliwinski P, Tonia T, Vestbo J, Wilson 
KC, Krishnan JA. Prevention of COPD exacerbations: a European Respiratory 
Society/American Thoracic Society guideline. Eur Respir J, 2017. 50(3). 
114. Patout M, Arbane G, Cuvelier A, Muir JF, Hart N, Murphy PB. 
Polysomnography versus limited respiratory monitoring and nurse-led titration 
to optimise non-invasive ventilation set-up: a pilot randomised clinical trial. 
Thorax. 2019; 74(1):83-86.  
115. Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, İber C, Kapur VK, MArcus 
CL, Mehra R, Parthasarathy S, Quan SF, Redline S, Strohl KP, Davidson Ward 
SL, Tangredi MM; American Academy of Sleep Medicine. Rules for scoring 
respiratory events in sleep: update of the 2007 AASM manual for the scoring 
of sleep and associated events. Deliberations of the Sleep Apnea Definitions 
 
 
Task Force of the American Academy of Sleep Medicine. J Clin Sleep 
Med 2012; 8: 597–619. 
116. Schwarz SB, Callegari J, Hamm C, Windisch W, Magnet FS. Is outpatient 
control of long-term non-invasive ventilation feasible in chronic obstructive 
pulmonary disease patients? Respiration. 2018; 95(3):154-160. 
117. Storre JH, Magnet FS, Dreher M, Windisch W. Transcutaneous 
monitoring as a replacement for arterial PCO2 monitoring during nocturnal 
non-invasive ventilation. Respiratory medicine. 2011 Jan 1; 105(1):143-50. 
118. Storre JH, Steurer B, Kabitz HJ, Dreher M, Windisch W. Transcutaneous 
PCO2 monitoring during initiation of noninvasive ventilation. Chest. 2007 Dec 
1;132(6):1810-6. 
119. Nardi J, Prigent H, Adala A, et al. Nocturnal oximetry and 
transcutaneous carbon dioxide in home ventilated neuromuscular patients. 
Respir Care 2012;57(9):1425-30 
120. Aarrestad S, Tollefsen E, Kleiven AL, Qvarfort M, Janssens JP, Skjønsberg 
OH. Validity of transcutaneous PCO2 in monitoring chronic hypoventilation 
treated with non-invasive ventilation. Respir Med 2016; 112:112–118. 
121. Kitajima T, Marumo S, Shima H, Shirata M, Kawashima S, Inoue D, 
Katayama Y, Itotani R, Sakuramoto M, Fukui M. Clinical impact of episodic 
nocturnal hypercapnia and its treatment with noninvasive positive pressure 
 
 
ventilation in patients with stable advanced COPD. Int J Chron Obstruct 
Pulmon Dis. 2018 Mar 6; 13:843-853. 
122. Huttmann SE, Windisch W, Storre JH. Techniques for the measurement 
and monitoring of carbon dioxide in the blood. Ann Am Thor Soc 
2014;11(4):645-652. 
123. Schwarz SB, Windisch W, Magnet FS, Schmoor C, Karagiannidis C, 
Callegari J, Huttmann SE, Storre JH. Continuous non-invasive PCO2 monitoring 
in weaning patients: Transcutaneous is advantageous over end-tidal PCO2. 
Respirology 2017; 22(8):1579-1584. 
124. Borel JC, Pelletier J, Taleux N, Briault A, Arnol N, Pison C, Tamisier R, 
Timsit JF, Pepin JL. Parameters recorded by software of noninvasive ventilators 
predict COPD exacerbation: a proof-of-concept study. Thorax 2015; 70(3):284–
285. 
125. Aarrestad S, Qvarfort M, Kleiven AL, Tollefsen E, Skjonberg OH, Janssens 
JP. Sleep related respiratory events during non-invasive ventilation of patients 
with chronic hypoventilation. Respir Med 2017; 132:210-216.  
126. Georges M, Attali V, Golmard JL, Morélot-Panzini C, Crevier-Buchman L, 
Collet JM, Tintignac A, Morawiec E, Trosini-Desert V, Salachas F, Similowski 
T, Gonzalez-Bermejo J. Reduced survival in patients with ALS with upper 
 
 
airway obstructive events on non-invasive ventilation. J Neurol Neurosurg 
Psychiatry. 2016 Oct; 87(10):1045-50 
127. Georges M, Adler D, Contal O, Espa F, Perrig S, Pepin JL, Janssens JP. 
Reliability of apnea-hypopnea index measured by a home bi-level pressure 
support ventilator versus a polysomnographic assessment. Respiratory Care 
2015; 60(7):1051-56. 
128. Chatwin M, Hawkins G, Panicchia L, Woods A, Hanak A, Lucas R, Baker 
E, Ramhmadany E, Mann B, Riley J, Cowie MR, Simonds AK. Randomized 
crossover tiral of telemonitoring in chronic respiratory patients (TeleCRAFT 
trial). Thorax 2016 Apr; 71(4):305-11. 
129. Adler D, Perrig S, Takahashi H, Espa F, Rodenstein D, Pépin JL, Janssens 
JP. Polysomnography in stable COPD under non-invasive ventilation to reduce 
patient-ventilator asynchrony and morning breathlessness. Sleep Breath 2012; 
16(4):1081–1090. 
130. Ramsay M, Mandal S, Suh ES, Steier J, Douiri A, Murphy PB, Polkey M, 
Simonds A, Hart N. Parasternal electromyography to determine the 
relationship between patient-ventilator asynchrony and nocturnal gas 
exchange during home mechanical ventilation set-up. Thorax 2015; 
70(10):946-52. 
 
 
 
 
Table 1. Recommendations for PICO (target population-intervention-
comparator-outcome) questions.  
Question Recommendation 
Should LTH-NIV be used in stable 
patients with COPD as compared to 
not using NIV? 
The ERS TF suggests LTH-NIV be 
used for patients with chronic stable 
hypercapnic COPD (conditional 
recommendation, low certainty 
evidence). 
Should LTH-NIV be used after an 
episode of acute hypercapnic 
respiratory failure in patients with 
COPD as compared to not using 
NIV? 
The ERS TF suggests LTH-NIV be 
used in patients with COPD 
following a life-threatening episode 
of acute hypercapnic respiratory 
failure requiring acute NIV, if 
hypercapnia persists following the 
episode (conditional 
recommendation, low certainty 
evidence). 
 
 
When using LTH-NIV in COPD 
patients, should NIV settings be 
titrated to normalize or at least 
cause a significant reduction in 
PaCO2 as compared to titrating not 
according to PaCO2 levels? 
The ERS TF suggests titrating LTH-
NIV to normalize or reduce PaCO2 
levels in patients with COPD 
(conditional recommendation, very 
low certainty evidence). 
When using LTH-NIV in COPD 
patients, should we use fixed 
pressure modes as compared to 
adaptive or auto-titrating pressure 
modes? 
The ERS TF suggests using fixed 
pressure support mode as first-
choice ventilator mode in patients 
with COPD using LTH-NIV 
(conditional recommendation, very 
low certainty evidence). 
 
 
COPD: Chronic obstructive pulmonary disease, LTH-NIV: Long-term home 
noninvasive ventilation, PaCO2: Partial pressure of carbon dioxide in arterial blood, 
ERS TF: European Respiratory Society Task Force. 
 
 
 
 
 
 
Table 2. Reproduced from Reference 14. 
 Strong recommendation  Weak recommendation 
For patients Most individuals in this 
situation would want the 
recommended course of 
action and only a small 
proportion would not. 
The majority of individuals 
in this situation would 
want the suggested 
course of action, but many 
would not. 
For clinicians Most individuals should 
receive the recommended 
course of action. 
Adherence to this 
recommendation 
according to the guideline 
could be used as a quality 
criterion or performance 
indicator. Formal decision 
aids are not likely to be 
needed to help individuals 
make decisions consistent 
with their values and 
Different choices are likely 
to be appropriate for 
different patients and 
therapy should be tailored 
to the individual patient‘s 
circumstances. Those 
circumstances may include 
the patient or family‘s 
values and preferences. 
 
 
preferences. 
For policy-makers The recommendation can 
be adapted as policy in 
most situations including 
for the use as 
performance indicators. 
Policy making will require 
substantial debates and 
involvement of many 
stakeholders. Policies are 
also more likely to vary 
between regions. 
Performance indicators 
would have to focus on 
the fact that adequate 
deliberation about the 
management options has 
taken place. 
 
 
 
 
 
 
 
 
 
Table 3. Future high-priority research questions. 
PICO 1 
LTH-NIV in chronic 
stable hypercapnic 
COPD 
Strategies for initiating NIV. It is obvious that 
ventilator setting and acclimatization to NIV are 
crucial for effectiveness, including better adherence. 
NIV may be initiated in the hospital or at home. In-
hospital initiation can be easily performed in some 
centers; however, it is more expensive and complex.  
The benefits of NIV in subgroups of patients with 
COPD. The variability of both adherence and 
treatment response may vary according to different 
clinical phenotypes. Indeed, it seems that the 
response is better in those patients with PaCO2 > 
50mmHg and PaCO2 reduction to normal following 
NIV. A phenogrouping strategy of hypercapnic COPD 
subgroups is needed for better defined the 
populations to be prioritized in further studies. 
The impact of comorbid conditions in this population 
e.g. the effect of obesity, OSA-overlap, cardiovascular 
diseases, and clinical frailty upon clinical outcome. 
 
 
Assessment of other underestimated factors, such as 
lack of social support and patient-ventilator 
asynchrony, which may impact the effectiveness of 
LTH-NIV. 
Cost effectiveness studies reporting the health 
economic value of LTH-NIVin chronic stable COPD. 
PICO 2 
LTH-NIV in COPD 
following an 
episode of acute 
hypercapnic 
respiratory failure 
Developing more accurate criteria for identifying 
patients who are likely to benefit from LTH-NIV, such 
as severity of illness (hypothesis that treatment of 
higher PaCO2 at initiation will drive greater clinical 
benefits), trajectory of hypercapnia recovery after 
exacerbation (as some patients return to eucapnia 
more rapidly than others) and treatment response 
(e.g. early reduction in PaCO2 level after starting LTH-
NIV, with the hypothesis that greater reduction in 
PaCO2 will drive greater clinical benefit).  
 
 
Physiological and biological mechanisms of action of 
LTH-NIV: physiological mechanisms determining 
reduction in PaCO2; the biological effects of PaCO2 
reduction in chronic hypercapnia upon immune, 
pulmonary vasculature, and skeletal muscle; biological 
mechanisms determining reduction in exacerbation; 
and physiological mechanisms determining enhanced 
sleep quality. 
The effects of NIV upon mental health and cognition 
upon patients, including effects upon HRQL and , 
cognitive function after an acute hypercapnic 
respiratory failure, the relationship between HRQL and 
cognitive function upon adherence and acceptability 
of LTH-NIV. 
Health service delivery research to promote the 
delivery of LTH-NIV after an acute hypercapnic 
respiratory failure to the right patient at the right 
time and prevent the ‗overuse‘ or ‗underuse‘ of the 
treatment.  
 
 
 Assessment of novel home treatments, e.g. high flow 
humidified nasal oxygen, that are capable of reducing 
PaCO2 in stable hypercapnic COPD patients. 
PICO 3  
LTH-NIV to 
normalize or 
reduce PaCO2 
The impact of NIV ventilator strategy targeted to 
maximise PaCO2 reduction compared to conventional 
ventilator modes on long-term clinical outcomes (i.e. 
hyperinflation, exacerbations, cardiovascular 
complications, hospitalisations, survival, costs, 
patient‘s adherence). 
PICO 4 
Fixed pressure vs 
new 
adaptive/auto-
titrating modes in 
LTH-NIV 
The role of adaptive/auto-titrating modes to improve 
the long-term outcome of COPD, acute exacerbation 
vs chronic stable hypercapnic COPD and optimization 
of overnight ventilation, especially in specific 
subgroups in which ventilatory requirements may vary 
substantially overnight. 
The assessment of auto-EPAP modes (in addition to 
adaptive/auto-titrating modes) in the sub-group of 
patients with COPD-OSA overlap syndrome 
 
 
The clinical efficacy and cost effectiveness of of auto-
titrating modes in the inpatient vs outpatient settings 
avoiding the need for hospitalization to initiate NIV, 
thereby increasing access to NIV. 
 
 
COPD: Chronic obstructive pulmonary disease, EPAP: Expiratory positive airway 
pressure, HRQL : Health related quality of life, LTH-NIV: Long-term home 
noninvasive ventilation, OSA: Obstructive sleep apnea, PaCO2: Partial pressure of 
carbon dioxide in arterial blood, ERS TF: European Respiratory Society Task Force 
 
 
 
 
  
 
 
 
Appendix.  Study comparators in trials included for PICO Question 1. 
Trials 
(Author, year) 
Comparator* 
Duiverman 2008 Standard of care 
Köhnlein 2014 Standard of care (LTOT if indicated) 
Eman Shebi 2015 Standard of care 
Zhou 2017 Standard of care 
Strumpf 1991 Standard of care 
Gay 1996 Sham NIV 
Kaminski 1999 LTOT alone 
Garrod 2000 Standard of care 
Casanova 2000 Standard of care 
Clini 2002 LTOT alone 
Sin 2007 Sham NIV 
McEvoy 2009 LTOT alone 
Bhatt 2013 Standard of care 
 
*Standard of care consists of pharmacological (inhaled and systematic treatments) 
and if present, nonpharmacological (pulmonary rehabilitation) therapies for the 
management of COPD. 
LTOT: Long term oxygen therapy, NIV: Noninvasive ventilation. 
 
GRADE Evidence Profile – Q1: NIV vs usual care in stable patients with COPD 
  
Certainty assessment № of patients Effect
Certainty Importance№ of 
studies Study design Risk of bias Inconsistency Indirectness Imprecision Other considerations Long-term NIV usual care
Relative  
(95% CI)
Absolute  
(95% CI)
Mortality (follow up: range 3 months to 12 months)
13 randomised 
trials 
serious a not serious not serious serious b none 78/422 (18.5%) 101/415 (24.3%) RR 0.86  
(0.58 to 1.27) 
34 fewer per 
1,000 
(from 66 more 
to 102 fewer) 
⨁⨁◯◯ 
LOW 
CRITICAL 
Number of Hospitalizations (follow up: range 3 months to 12 months)
3 randomised 
trials 
serious a not serious c not serious serious b none 154 154 - MD 1.26 
fewer  
(2.59 fewer to 
0.08 more) 
⨁⨁◯◯ 
LOW 
CRITICAL 
Quality of Life (higher is better) (follow up: range 3 months to 12 months; assessed with: Multiple validated scales)
7 randomised 
trials 
serious a serious d not serious serious b none 244 244 - SMD 0.49 SD 
higher 
(0.01 lower to 
0.98 higher) 
⨁◯◯◯ 
VERY LOW 
CRITICAL 
Change in Dyspnea Score (assessed with: lower is better)
5 randomised 
trials 
serious a not serious not serious not serious none 92 96 - SMD 0.51 SD 
lower 
(0.95 lower to 
0.06 lower) 
⨁⨁⨁◯  
MODERATE 
CRITICAL 
Change in PaCO2 (follow up: range 3 months to 12 months; assessed with: mmHg)
12 randomised 
trials 
serious a not serious c not serious not serious none 374 373 - MD 3.37 
mmHg lower 
(5.75 lower to 
0.99 lower) 
⨁⨁⨁◯  
MODERATE 
IMPORTANT 
Change in PaO2 (follow up: range 3 months to 12 months; assessed with: mmHg)
9 randomised 
trials 
serious a not serious not serious not serious none 278 277 - MD 3.09 
mmHg higher 
(1.45 higher to 
4.74 higher) 
⨁⨁⨁◯  
MODERATE 
IMPORTANT 
Change in FEV1 (follow up: range 3 months to 12 months; assessed with: % or L)
10 randomised 
trials 
serious a not serious not serious serious e none 366 374 - SMD 0.07 SD 
higher 
(0.14 lower to 
0.27 higher) 
⨁⨁◯◯ 
LOW 
IMPORTANT 
Change in FVC (follow up: range 3 months to 12 months; assessed with: & or L)
8 randomised 
trials 
serious a not serious not serious serious e none 287 296 - SMD 0.1 SD 
higher 
(0.06 lower to 
0.26 higher) 
⨁⨁◯◯ 
LOW 
IMPORTANT 
Change in 6 minute walk distance (follow up: range 3 months to 12 months; assessed with: metres)
CI: Confidence interval; RR: Risk ratio; MD: Mean difference; SMD: Standardised mean difference 
Explanations 
a. Most trials unblinded, variable lost-to-follow up which was significant in some included trials.  
b. Wide confidence intervals that do not exclude significant harm.  
c. High Isqaured (>70%) however in most included studies point estimate is on the side of benefit.  
d. High Isquared (>70%) and variable effects between studies.  
e. No effect, however confidence intervals don't exclude significant benefit or harm.  
f. Wide confidence intervals that do not exclude benefit.  
g. Varying importance and severity of these minor adverse effects.  
10 randomised 
trials 
serious a not serious not serious not serious none 256 260 - MD 32.03 
metres 
higher 
(10.79 higher 
to 53.26 
higher) 
⨁⨁⨁◯  
MODERATE 
IMPORTANT 
Change in Sleep Efficiency (follow up: range 3 months to 12 months)
3 randomised 
trials 
serious a not serious not serious serious f none 61 65 - SMD 0.55 SD 
lower 
(1.13 lower to 
0.03 higher) 
⨁⨁◯◯ 
LOW 
IMPORTANT 
Minor Adverse Events (follow up: range 3 months to 12 months; assessed with: discomfort, skin break or rash)
3 randomised 
trials 
serious a not serious serious g not serious none 27/189 (14.3%) 0/175 (0.0%) RR 10.35 
(2.45 to 43.71) 
0 fewer per 
1,000 
(from 0 fewer 
to 0 fewer) 
⨁⨁◯◯ 
LOW 
IMPORTANT 
Certainty assessment № of patients Effect
Certainty Importance№ of 
studies Study design Risk of bias Inconsistency Indirectness Imprecision Other considerations Long-term NIV usual care
Relative  
(95% CI)
Absolute  
(95% CI)
Forest plot 1: Mortality 
Forest plot 2: Hospitalizations 
Forest plot 3: Quality of Life 
Forest plot 4: Dyspnea 
Forest plot 5: PCO2 
Forest plot 6: PO2 
Forest plot 7: FEV1 
Forest plot 8: Six minute walk distance 
Forest plot 9:  Sleep efficiency 
Forest plot 10: Minor adverse events
Forest plot 11: Mortality subgroup analysis - targeted PCO2 vs. non-targeted PCO2 
Forest plot 12: Quality of Life subgroup analysis - targeted PCO2 vs. non-targeted PCO2 
Forest plot 13: PCO2 subgroup analysis - targeted PCO2 vs. non-targeted PCO2 
Forest plot 14: PO2 subgroup analysis - targeted PCO2 vs. non-targeted PCO2 
Forest plot 15: FEV1 subgroup analysis - targeted PCO2 vs. non-targeted PCO2 
Forest plot 16: Six minute walk distance subgroup analysis - targeted PCO2 vs. non-targeted PCO2 
GRADE Evidence Profile – Q2: NIV vs usual care after an exacerbation of COPD 
Certainty assessment № of patients Effect
Certainty Importance№ of 
studies
Study 
design
Risk of 
bias Inconsistency Indirectness Imprecision
Other consid-
erations
Long-term 
NIV
Usual 
care
Relative

(95% CI)
Absolute

(95% CI)
Mortality (follow up: range 1 years to 2 years)
4 RCTs serious a not serious not serious serious b none 55/201 
(27.4%)
62/205 
(30.2%)
RR 0.92 
(0.67 to 
1.25)
24 fewer per 1,000 
(from 76 more to 100 fewer) ⨁⨁◯◯ 
LOW
CRITICAL
Exacerbations per year (follow up: range 1 years to 2 years)
3 RCTs serious c not serious not serious serious b none 181 185 - SMD 0.19 SD lower 
(0.40 lower to 0.01 higher) ⨁⨁◯◯ 
LOW
CRITICAL
Hospitalizations (follow up: range 1 years to 2 years)
3 RCTs serious a serious d not serious serious b none 71/181 
(39.2%)
93/185 
(50.3%)
RR 0.61 
(0.30 to 
1.24)
196 fewer per 1,000 
(from 121 more to 352 
fewer)
⨁◯◯◯ 
VERY LOW
CRITICAL
Dyspnea score (follow up: range 1 years to 2 years; assessed with: Medical Research Council Dyspnea (MRC) Score)
2 RCTs serious c not serious e not serious serious b none 69 71 - MD 0.8 lower 
(2.17 lower to 0.58 higher)
⨁⨁◯◯ 
LOW
CRITICAL
Quality of Life (follow up: range 1 years to 2 years; assessed with: Severe Respiratory Insufficiency Questionnaire)
2 RCTs serious c not serious e not serious serious b none 85 77 - MD 2.89 points higher 
(6.8 higher to 1.03 lower) ⨁⨁◯◯ 
LOW
CRITICAL
PaO2 (follow up: range 6 months to 2 years)
4 RCTs serious c serious d not serious serious b none 107 99 - MD 1.53 mmHg lower 
(4.24 lower to 1.17 higher) ⨁◯◯◯ 
VERY LOW
IMPORTANT
PaCO2 (follow up: range 6 months to 2 years)
5 RCTs serious c not serious not serious not serious none 134 126 - MD 3.41 mmHg lower 
(4.09 lower to 2.73 lower)
⨁⨁⨁◯ 
MODERATE
IMPORTANT
Exercise tolerance (follow up: range 6 months to 2 years; assessed with: 6 minute walk test)
CI: Confidence interval; RCT: Randomized controlled trial; RR: Risk ratio; MD: Mean difference; SMD: Standardised mean difference 
Explanations 
a. Lack of blinding of patients and clinicians which could result in cointervention. 
b. Wide 95% confidence intervals which do not exclude significant benefit nor significant harm. 
c. Lack of blinding of patients and clinicians in most studies which could result in cointervention and/or biased assessment of subjective outcomes, as well as significant loss to follow-up for end-of-
study measurements. 
d. I-squared (I^2) values high, with individual studies on different sides of the line of no effect. 
e. Though high I-squared (I^2) values, all point estimates are on the side of benefit. 
f. Very high I-squared (I^2) values with studies on each side of the line of no effect. 
2 RCTs serious c very serious f not serious serious b none 30 25 - MD 8.64 m lower 
(209 lower to 192 higher) ⨁◯◯◯ 
VERY LOW
IMPORTANT
FEV1 (follow up: range 6 months to 1 years)
2 RCTs serious c not serious not serious serious b none 58 51 - SMD 0.36 SD lower 
(0.74 lower to 0.03 higher)
⨁⨁◯◯ 
LOW
IMPORTANT
Forest plot 1: Mortality 
Forest plot 2: Exacerbations 
Forest plot 3: Hospitalizations 
Forest plot 4: Dyspnea 
Forest plot 6: Quality of life 
Forest plot 6: PCO2 
Forest plot 7: PO2 
Forest plot 8: Exercise tolerance 
Forest plot 9: Pulmonary function- FEV1 
GRADE Evidence Profile – Q3:  NIV with targeted normalization of PaCO2 levels compared to NIV without targeting normal PaCO2 level 
for long-term NIV in COPD patients  
CI: Confidence interval; MD: Mean difference 
Explanations 
a. Unblinded intervention may affect co-intervention use. Crossover study with potential for carryover effect.  
b. Wide confidence intervals don't exclude significant harm or significant benefit.  
c. Small number of patients limit precision.  
Certainty assessment № of patients Effect
Certainty Importance
№ of 
studies Study design Risk of bias Inconsistency Indirectness Imprecision Other considerations
NIV with targeted 
normalization of 
PaCO2 levels
NIV without 
targeting normal 
PaCO2 level
Relative  
(95% CI)
Absolute  
(95% CI)
Quality of Life (follow up: mean 6 weeks; assessed with: SRI-SS score (higher is better))
3 randomised 
trials 
serious a not serious not serious serious b,c none 34 36 - MD 0.95 
points lower 
(8.33 lower to 
6.42 higher) 
⨁⨁◯◯ 
LOW 
CRITICAL 
Dyspnea (follow up: mean 6 weeks; assessed with: Borg score)
1 randomised 
trials 
serious a not serious not serious serious c none 15 15 - MD 1.54 
points higher 
(0.56 higher to 
2.52 higher) 
⨁⨁◯◯ 
LOW 
CRITICAL 
FEV1 (follow up: mean 6 weeks; assessed with: L)
1 randomised 
trials 
serious a not serious not serious serious b,c none 11 14 - MD 0.04 L 
higher 
(0.34 lower to 
0.42 higher) 
⨁⨁◯◯ 
LOW 
IMPORTANT 
PaCO2 (follow up: mean 6 weeks; assessed with: mmHg)
5 randomised 
trials 
serious a not serious not serious serious c none 65 68 - MD 4.93 
mmHg lower 
(7.43 lower to 
2.42 lower) 
⨁⨁◯◯ 
LOW 
IMPORTANT 
PaO2 (follow up: mean 6 weeks; assessed with: mmHg)
3 randomised 
trials 
serious a not serious not serious serious b,c none 39 39 - MD 3.4 
mmHg higher 
(2.39 lower to 
9.19 higher) 
⨁⨁◯◯ 
LOW 
IMPORTANT 
6MWD (follow up: mean 6 weeks; assessed with: metres)
1 randomised 
trials 
serious a not serious not serious serious b,c none 15 15 - MD 14 
metres 
higher 
(70.42 lower 
to 98.42 
higher) 
⨁⨁◯◯ 
LOW 
IMPORTANT 
Sleep Comfort (follow up: mean 6 weeks; assessed with: VAS scale)
1 randomised 
trials 
serious a not serious not serious very serious b,c none 8 7 - MD 1 cm 
higher 
(28.42 lower 
to 30.42 
higher) 
⨁◯◯◯ 
VERY LOW 
IMPORTANT 
Forest plot 1: Quality of Life 
Forest plot 2: PCO2 
Forest plot 3: PO2 
Question 4: Adaptive ventilatory modes in long-term NIV for COPD

CI: Confidence interval; SMD: Standardised mean difference; MD: Mean difference 
Explanations 
a. Lack of blinding which could result in cointervention, or affect judgement of subjective outcomes. 
b. Wide 95% confidence interval which fails to exclude significant benefit or harm. 
c. Most studies did not use a validated instrument to assess sleep quality. 
Certainty assessment № of patients Effect
Certainty Importance№ of 
studies
Study 
design
Risk of 
bias Inconsistency Indirectness Imprecision
Other consid-
erations
Adaptive 
NIV
Conventional 
NIV
Relative

(95% CI)
Absolute

(95% CI)
Quality of Life (follow up: range 2 months to 3 months; assessed with: Severe Respiratory Insufficiency Questionnaire (1 study); St. George's Respiratory Questionnaire (2 studies))
3 RCTs serious a not serious not serious serious b none 54 54 - SMD 0.28 SD 
higher 
(0.66 higher to 
0.1 lower)
⨁⨁◯◯ 
LOW
CRITICAL
Sleep quality (follow up: range 1 days to 3 months; assessed with: Visual analogue scale (2 studies); unvalidated questionnaire (2 studies); Epworth Sleepiness Scale (1 study))
5 RCTs serious a not serious serious c serious b none 80 80 - SMD 0.14 
lower 
(0.53 lower to 
0.26 higher)
⨁◯◯◯ 
VERY LOW
IMPORTANT
Exercise tolerance (follow up: range 2 months to 3 months; assessed with: Shuttle walk test (2 studies); 6 minute walk test (1 study))
3 RCTs serious a not serious not serious serious b none 47 47 - SMD 0.1 
lower 
(0.51 lower to 
0.3 higher)
⨁⨁◯◯ 
LOW
IMPORTANT
PaCO2 (follow up: range 1 days to 3 months)
6 RCTs serious a not serious not serious serious b none 91 91 - MD 1.95 
mmHg lower 
(4.29 lower to 
0.4 higher)
⨁⨁◯◯ 
LOW
IMPORTANT
Oxygenation (follow up: range 1 days to 3 months; assessed with: PaO2, or SaO2 oximetry)
6 RCTs serious a not serious not serious serious b none 91 91 - SMD 0.04 
lower 
(0.33 lower to 
0.26 higher)
⨁⨁◯◯ 
LOW
IMPORTANT
Forest plot 1: Quality of Life 
Forest plot 2: Sleep quality 
Forest plot 3: Exercise tolerance 
Forest plot 4: PCO2 
Forest plot 5: PO2
ASSESSMENT
Problem
Is  the problem a priority?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ No
○ Probably no
○ Probably yes
● Yes
○ Varies
○ Don't know
The panel decided on these PICO questions in 
advance of the guideline meeting on the basis of 
their importance to clinical practice. 
Desirable Effects
How substantial are the desirable anticipated effects?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Trivial
○ Small
○ Moderate
● Large
○ Varies
○ Don't know
Desirable
Quality of life increased (0.49 SD higher)
Reduced dyspnea score (0.51 SD lower). Really key-- this is  a critical outcome 
for patients. 
Small improvement in 6 minute walk test (~30 m longer)
Undesirable
Slightly lower s leep efficency (0.55 SD lower)
Significant concerns raised about the 
heterogeneity of ventilatory settings-- do studies 
with higher CO2 clearance or settings demonstrate 
a greater effect? 
Further analysis requested on settings and 
whether or not there are other effects. Sensitivity 
analysis done looking at high-vs-low CO2 targeting. 
QUESTION
Should Long-term NIV vs. usual care be used for stable patients with COPD?
POPULATION: stable patients with COPD
INTERVENTION: Long-term NIV
COMPARISON: usual care
MAIN
OUTCOMES:
Mortality; Number of Hospitalizations; Quality of Life (higher is  better); Change in Dyspnea Score ; Change in PaCO2; Change in PaO2; Change in FEV1; 
Change in FVC; Change in 6 minute walk distance; Change in Sleep Efficiency; Minor Adverse Events;
SETTING:
PERSPECTIVE:
BACKGROUND:
CONFLICT OF
INTERESTS:
Increase in minor adverse events eg skin breakdown etc. (10 fold increase)
Neutral/little effect
Reduced mortality with NIV (14%) -not explicitly respiratory causes; and 
potentially high rate of dropouts, but imprecise with wide 95% CI.
Reduced hopsitalizations (mean 1.26 fewer), but imprecise with wide 95% CI
No significant effect upon FEV1 or FVC.
Studies targeting normal CO2 had stronger s ignal 
for benefit of NIV. 
Undesirable Effects
How substantial are the undesirable anticipated effects?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Large
○ Moderate
● Small
○ Trivial
○ Varies
○ Don't know
Desirable
Quality of life increased (0.49 SD higher)
Reduced dyspnea score (0.51 SD lower). Really key-- this is  a critical outcome 
for patients. 
Small improvement in 6 minute walk test (~30 m longer)
Undesirable
Slightly lower s leep efficency (0.55 SD lower)
Increase in minor adverse events eg skin breakdown etc. (10 fold increase)
Neutral/little effect
Reduced mortality with NIV (14%) -not explicitly respiratory causes; and 
potentially high rate of dropouts, but imprecise with wide 95% CI.
Reduced hopsitalizations (mean 1.26 fewer), but imprecise with wide 95% CI
No significant effect upon FEV1 or FVC.
Dropout is  also a concern here. Those that did not 
tolerate NIV fell out and therefore not exposed to 
benefit. (getting at lack of adherence as well) 
Meecham-Jones study data missing for s leep 
quality, though unlikely to change effects.
Certainty of evidence
What is  the overall certainty of the evidence of effects?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Very low
● Low
○ Moderate
○ High
○ No included studies
Moderate certainty for dyspnea scores, changes in PaO2, PCO2.
Low or very low certainty evidence for all other outcomes
Values
Is  there important uncertainty about or variability in how much people value the main outcomes?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Important uncertainty or
variability
● Possibly important uncertainty
or variability
○ Probably no important
uncertainty or variability
○ No important uncertainty or
variability
Exacerbations, dyspnea, and quality of life are among the most important 
outcomes in patients with COPD. Symptom relief was generally found to be 
more important than adverse events. PMID: 30002103
Balance of effects
Does the balance between desirable and undesirable effects favor the intervention or the comparison?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Favors the comparison
○ Probably favors the
comparison
○ Does not favor either the
intervention or the comparison
● Probably favors the
intervention
○ Favors the intervention
○ Varies
○ Don't know
The onyl negative effects see were s leep efficiency 
and minor adverse events; most other outcomes 
were positive (QOL, dyspnea, exercise tolerance) 
or neutral. Of note, mortality and hospitalizations 
the s ignal is  towards benefit, which is  reassuring. 
Resources required
How large are the resource requirements (costs)?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Large costs
● Moderate costs
○ Negligible costs and savings
○ Moderate savings
○ Large savings
○ Varies
○ Don't know
The estimated costs of providing a domiciliary NIV service are reported in 
Table 34 and for NIV were £2373 in the first year and £1536 in subsequent 
years. This estimate was in between cost estimates reported in the two 
studies identified in the clinical review. Tuggey et al. (2003)40 estimate 
domiciliary NIV to cost £1060 per year in 2003 prices, which converts to £1344 
in 2012 prices (assuming a 3% inflation rate), and Clini et al. (2009)134 
estimated NIV to cost €1920 in 2008 prices, which converts to £2727 
(converting to GBP at the mid-year conversion rate of 1.263168 and inflating to 
2012 prices at a rate of 3%). 
Certainty of evidence of required resources
What is  the certainty of the evidence of resource requirements (costs)?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Very low
● Low
○ Moderate
○ High
○ No included studies
Low certainty as the cost and avialability of 
resources for NIV may vary greatly across 
settings.
Cost effectiveness
Does the cost-effectiveness of the intervention favor the intervention or the comparison?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Favors the comparison
○ Probably favors the
comparison
○ Does not favor either the
intervention or the comparison
● Probably favors the
intervention
○ Favors the intervention
○ Varies
○ No included studies
Economic modelling suggested that NIV may be cost-effective in a stable 
population at a
threshold of £30,000 per quality-adjusted life-year (QALY) gained (incremental 
cost-effectiveness ratio
£28,162), but this is  associated with uncertainty. In the case of the post-
hospital population, results for
three separate base cases ranged from usual care dominating to NIV being 
cost-effective, with an
incremental cost-effectiveness ratio of less than £10,000 per QALY gained. All 
estimates were sensitive
  suggested that reductions in the rate of hospital admissions per patient per 
year of 24% and 15% in the
stable and post-hospital populations, respectively, are required for NIV to be 
cost-effective.
The group vascillated between "Favours the 
intervention" vs. "Probably favours the 
intervention." All agreed towards the s ide of cost 
effectiveness of NIV vs. comparison.
Equity
What would be the impact on health equity?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Reduced
○ Probably reduced
○ Probably no impact
○ Probably increased
○ Increased
○ Varies
○ Don't know
COPD patients disproportionately come from 
disadvantaged populations, so treating COPD may 
improve equity. In low or middle income 
countries/populations, home NIV may not be 
feasible and a recommendation for NIV may 
exacerbate health equity vs. more financially 
adventageous regions.
Acceptability
Is  the intervention acceptable to key stakeholders?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ No
○ Probably no
○ Probably yes
● Yes
○ Varies
○ Don't know
Many clinicians would find NIV acceptable due to its  
use in acute exacerbations-- it is  a familiar therapy 
to those who treat COPD.
Patients may vary with regard to acceptability of 
NIV in the long-term settings, however if it 
improves dyspnea and quality of life it may be 
acceptable. 
Feasibility
Is  the intervention feasible to implement?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ No
○ Probably no
○ Probably yes
○ Yes
● Varies
○ Don't know
Some regions may not have infrastructure to 
support this; however there is  widespread use of 
NIV in other countries which can provide practice 
models to guide practice. This will vary depending 
on the health care system, resources, and patient 
location.
SUMMARY OF JUDGEMENTS
JUDGEMENT
PROBLEM No Probably no Probably yes Yes Varies Don't know
DESIRABLE EFFECTS Trivial Small Moderate Large Varies Don't know
UNDESIRABLE EFFECTS Large Moderate Small Trivial Varies Don't know
CERTAINTY OF EVIDENCE Very low Low Moderate High
No included
studies
VALUES
Important
uncertainty or
variability
Possibly
important
uncertainty or
variability
Probably no
important
uncertainty or
variability
No important
uncertainty or
variability
BALANCE OF EFFECTS
Favors the
comparison
Probably favors
the comparison
Does not favor
either the
intervention or the
comparison
Probably favors
the intervention
Favors the
intervention
Varies Don't know
RESOURCES REQUIRED Large costs Moderate costs Negligible costs
and savings
Moderate savings Large savings Varies Don't know
CERTAINTY OF EVIDENCE
OF REQUIRED
RESOURCES
Very low Low Moderate High
No included
studies
COST EFFECTIVENESS
Favors the
comparison
Probably favors
the comparison
Does not favor
either the
intervention or the
comparison
Probably favors
the intervention
Favors the
intervention
Varies
No included
studies
EQUITY Reduced Probably reduced
Probably no
impact
Probably increased Increased Varies Don't know
ACCEPTABILITY No Probably no Probably yes Yes Varies Don't know
FEASIBILITY No Probably no Probably yes Yes Varies Don't know
TYPE OF RECOMMENDATION
CONCLUSIONS
Recommendation
The ERS TF suggests long-term NIV be used for patients with chronic stable hypercapnic COPD (conditional recommendation, low certainty evidence).
Justification
Most outcomes favour NIV, including patient-important outcomes of dyspnea, QOL, exercise tolerance, with reassuring s ignal for mortality and exacerbations (towards 
benefit of NIV), and few harms (minor reduction in s leep efficacy and minor adverse events). Factors such as cost, acceptability, feasibility probably in favour though could 
vary between patients and settings. Overall balance of effects favour NIV though certainty of evidence is  low, hence the panel chose a conditional/weak recommendation 
for NIV only; this allows a tailored approach to patient and setting-specific conditions as well.
Strong recommendation against
the intervention
Conditional recommendation
against the intervention
Conditional recommendation for
either the intervention or the
comparison
Conditional recommendation
for the intervention
Strong recommendation for the
intervention
○ ○ ○ ● ○
Subgroup considerations
We examined the subgroup of studies which targeted normal CO2 (generally newer studies). The s ignal if anything was for more benefit of NIV if lower CO2 targeted, again 
suggesting hypercapnic patients derive the most benefit from NIV.
Implementation considerations
The panel recognized that the acceptability, feasibility, and costs of NIV vary greatly. For some patients and clinicans, the potential benefits (dyspnea, QOL, exercise 
tolerance; possible reduction in hospitalizations, though imprecise evidence) may not be worth it. This is  consistent with a conditional recommendation in GRADE. 
Monitoring and evaluation
See research priorities, below.
Research priorities
 1) Strategies for initiating NIV. It is  obvious that ventilator setting and acclimatization to NIV are crucial for effectiveness, including better adherence. NIV may be initiated 
in the hospital or at home. In-hospital initiation can be easily performed in some centers; however, it is  more expensive and complex. 
 
2) The benefits of NIV in subgroups of patients with COPD. The variability of both adherence and treatment response may vary according to different clinical phenotypes. 
Indeed, it seems that the response is  better in those patients with PaCO2 > 50mmHg and PaCO2 reduction to normal following NIV. A phenogrouping strategy of 
hypercapnic COPD subgroups is  needed for better defined the populations to be prioritized in further studies.
 
3) The impact of comorbid conditions in this population e.g. the effect of obesity, OSA-overlap, cardiovascular diseases, and clinical frailty upon clinical outcome.
 
4) Assessment of other underestimated factors, such as lack of social support and patient-ventilator asynchrony, which may impact the effectiveness of long-term NIV.
 
5) Cost effectiveness studies reporting the health economic value of long-term NIV in chronic stable COPD.
ASSESSMENT
Problem
Is  the problem a priority?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ No
○ Probably no
○ Probably yes
● Yes
○ Varies
○ Don't know
The panel decided on these PICO questions in 
advance of the guideline meeting on the basis of 
their importance to clinical practice. 
Desirable Effects
How substantial are the desirable anticipated effects?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Trivial
○ Small
● Moderate
○ Large
○ Varies
○ Don't know
Desirable effect
Exacerbations-- small reduction, but imprecise (SMD -0.19 exacerbations, -0.4 
to 0.01)
Hospitalizations-- small reduction, but imprecise (RR 0.61, 95%CI 0.30 to 1.24)
Reduction in PCO2 (-3.41 mmHg)
Dyspnea (MD -0.80)
Limited evidence based for this discussion. Small 
sample s ize and number of trials  limit precis ion. 
May be a reduction in exacerbations and 
hospitalizations but limited by imprecis ion; other 
patient important outcomes likely also favour NIV 
but again issues with imprecis ion.
QUESTION
Should Long-term NIV vs. usual care be used for patients with COPD after an acute hypercapnic respiratory
failure episode?
POPULATION: patients with COPD after an acute hypercapnic respiratory failure episode
INTERVENTION: Long-term NIV
COMPARISON: usual care
MAIN
OUTCOMES:
Mortality; Exacerbations; Hospitalizations; Dyspnea score; Quality of Life; PaO2; PaCO2; Exercise tolerance; FEV1;
SETTING:
PERSPECTIVE:
BACKGROUND:
CONFLICT OF
INTERESTS:
Quality of life (MD -2.89 measured using SRI)
Undesirable effect
PO2 MD 1.53 mmHg
Little to no effect
Mortality RR 0.92
Exercise tolerance MD 8.64 
Inclusion of Chung study which is  considered to be 
at high risk of bias may limit interpretation of 
some outcome (eg. exacerbations).  Sensitivity 
analysis including and excluding Chung has 
minimal impact upon point estimates; including 
increases precis ion s lightly. 
TIming of initiation is  also an important 
consideration-- HOT-HMV demonstrated reduction 
in exacerbations in select population of patients 
who remain hypercapenic ~2-4 weeks after their 
exacerbation; this is  the subgroup most likely to 
benefit and possibly why smaller benefits seen 
with Struik. Sensitivity analysis excluding RESCUE 
trial demonstrates statistical s ignificance for 
reduction in events; unfortunately no subgroup of 
persistent hypercapnia from Struik et all to 
compare. 
Undesirable Effects
How substantial are the undesirable anticipated effects?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Large
○ Moderate
● Small
○ Trivial
○ Varies
○ Don't know
Desirable effect
Exacerbations-- small reduction, but imprecise (SMD -0.19 exacerbations, -0.4 
to 0.01)
Hospitalizations-- small reduction, but imprecise (RR 0.61, 95%CI 0.30 to 1.24)
Reduction in PCO2 (-3.41 mmHg)
Dyspnea (MD -0.80)
Quality of life (MD -2.89 measured using SRI)
Undesirable effect
PO2 MD 1.53 mmHg
Little to no effect
Mortality RR 0.92
Exercise tolerance MD 8.64 
Even though not reflected in this evidence base,  
adverse events from Q1 also apply here as 
indirect evidence as presumably the mask and 
interfaces have the same effects whether used 
early after exacerbation or later in stable phase.
Its possible that newer techniques and newer 
interfaces have less s ide effects.
Certainty of evidence
What is  the overall certainty of the evidence of effects?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Very low
● Low
Low for almost all outcomes due to imprecis ion.
○ Moderate
○ High
○ No included studies
Values
Is  there important uncertainty about or variability in how much people value the main outcomes?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Important uncertainty or
variability
● Possibly important uncertainty
or variability
○ Probably no important
uncertainty or variability
○ No important uncertainty or
variability
Exacerbations, dyspnea, and quality of life are among the most important 
outcomes in patients with COPD. Symptom relief was generally found to be 
more important than adverse events. PMID: 30002103 
Balance of effects
Does the balance between desirable and undesirable effects favor the intervention or the comparison?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Favors the comparison
○ Probably favors the
comparison
○ Does not favor either the
intervention or the comparison
● Probably favors the
intervention
○ Favors the intervention
○ Varies
○ Don't know
Probably favors the intervention, especially in 
subgroup of patients with persistent hypercapnia 
2-4 weeks post exacerbation as seen in HOT-HMV 
trial. Reduction of events is  of great importance to 
patients. Possibly improvements in QOL and 
dyspnea as well. All outcomes limited by 
imprecis ion. 
ALso, little evidence of harm from NIV-- suspect 
that still occurs-- will assume similar rates of 
minor adverse reactions as in PICO 1, as mask fit 
etc. likely s imilar in post-exacerbation as chronic 
stable population. 
Resources required
How large are the resource requirements (costs)?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Large costs
● Moderate costs
○ Negligible costs and savings
The estimated costs of providing a domiciliary NIV service are reported in 
Table 34 and for NIV were £2373 in the first year and £1536 in subsequent 
years. This estimate was in between cost estimates reported in the two 
○ Moderate savings
○ Large savings
○ Varies
○ Don't know
studies identified in the clinical review. Tuggey et al. (2003)40 estimate 
domiciliary NIV to cost £1060 per year in 2003 prices, which converts to £1344 
in 2012 prices (assuming a 3% inflation rate), and Clini et al. (2009)134 
estimated NIV to cost €1920 in 2008 prices, which converts to £2727 
(converting to GBP at the mid-year conversion rate of 1.263168 and inflating to 
2012 prices at a rate of 3%). 
Certainty of evidence of required resources
What is  the certainty of the evidence of resource requirements (costs)?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Very low
● Low
○ Moderate
○ High
○ No included studies
Low certainty as the cost and avialability of 
resources for NIV may vary greatly across settings 
. 
Cost effectiveness
Does the cost-effectiveness of the intervention favor the intervention or the comparison?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Favors the comparison
○ Probably favors the
comparison
○ Does not favor either the
intervention or the comparison
● Probably favors the
intervention
○ Favors the intervention
○ Varies
○ No included studies
Economic modelling suggested that NIV may be cost-effective in a stable 
population at a
threshold of £30,000 per quality-adjusted life-year (QALY) gained (incremental 
cost-effectiveness ratio
£28,162), but this is  associated with uncertainty. In the case of the post-
hospital population, results for
three separate base cases ranged from usual care dominating to NIV being 
cost-effective, with an
incremental cost-effectiveness ratio of less than £10,000 per QALY gained. All 
estimates were sensitive
to effectiveness estimates, length of benefit from NIV (currently unknown) and 
some costs. Modelling
suggested that reductions in the rate of hospital admissions per patient per 
year of 24% and 15% in the
stable and post-hospital populations, respectively, are required for NIV to be 
Probably favours NIV in hypercapnic, "frequent 
flyer" population with recurrent hospitalizations 
and exacerbations.
cost-effective.
Equity
What would be the impact on health equity?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Reduced
○ Probably reduced
○ Probably no impact
○ Probably increased
○ Increased
● Varies
○ Don't know
COPD patients disproportionately come from 
disadvantaged populations, so treating COPD may 
improve equity. In low or middle income 
countries/populations, home NIV may not be 
feasible and a recommendation for NIV may 
exacerbate health equity vs. more financially 
adventageous regions. 
Acceptability
Is  the intervention acceptable to key stakeholders?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ No
○ Probably no
● Probably yes
○ Yes
○ Varies
○ Don't know
Many clinicians would find NIV acceptable due to its  
use in acute exacerbations-- it is  a familiar therapy 
to those who treat COPD. This may be more 
acceptable in this post-acute exacerbation setting 
than the chronic COPD setting as the transition 
from acute to long-term NIV. 
Patients may vary with regard to acceptability of 
NIV in the long-term settings, however if it 
improves dyspnea and quality of life and 
exacerbations it may be acceptable. 
Feasibility
Is  the intervention feasible to implement?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ No
○ Probably no
● Probably yes
○ Yes
○ Varies
○ Don't know
May be more feasible than Q1 as clinical pathways 
exist pre- and post-discharge to facilitate initiation 
of NIV (eg. inpatient respirology consultation, 
arrange for equipment while still in hospital, etc).
SUMMARY OF JUDGEMENTS
JUDGEMENT
PROBLEM No Probably no Probably yes Yes Varies Don't know
DESIRABLE EFFECTS Trivial Small Moderate Large Varies Don't know
UNDESIRABLE EFFECTS Large Moderate Small Trivial Varies Don't know
CERTAINTY OF EVIDENCE Very low Low Moderate High
No included
studies
VALUES
Important
uncertainty or
variability
Possibly
important
uncertainty or
variability
Probably no
important
uncertainty or
variability
No important
uncertainty or
variability
BALANCE OF EFFECTS
Favors the
comparison
Probably favors
the comparison
Does not favor
either the
intervention or the
comparison
Probably favors
the intervention
Favors the
intervention
Varies Don't know
RESOURCES REQUIRED Large costs Moderate costs
Negligible costs
and savings
Moderate savings Large savings Varies Don't know
CERTAINTY OF EVIDENCE
OF REQUIRED
RESOURCES
Very low Low Moderate High
No included
studies
COST EFFECTIVENESS
Favors the
comparison
Probably favors
the comparison
Does not favor
either the
intervention or the
comparison
Probably favors
the intervention
Favors the
intervention
Varies
No included
studies
EQUITY Reduced Probably reduced
Probably no
impact
Probably increased Increased Varies Don't know
ACCEPTABILITY No Probably no Probably yes Yes Varies Don't know
FEASIBILITY No Probably no Probably yes Yes Varies Don't know
TYPE OF RECOMMENDATION
Strong recommendation against
the intervention
Conditional recommendation
against the intervention
Conditional recommendation for
either the intervention or the
comparison
Conditional recommendation
for the intervention
Strong recommendation for the
intervention
○ ○ ○ ● ○
CONCLUSIONS
Recommendation
The ERS TF suggests long-term NIV be used in patients with COPD following a life-threatening episode of acute hypercapnic respiratory failure requiring acute NIV, if 
hypercapnia persists beyond 2-4 weeks following the episode (conditional recommendation, low certainty evidence).
Justification
Generally low certainty of evidence, but most important outcomes are neutral (mortality, exercise tolerance) or favour NIV (exacerbations, hospitalizations, HRQOL 
measured using SRI) without any major harms seen. Reduction in events seen in HOT-HMV trial likely because that trial included patients with persistent hypercapnia some 
time (2-4 weeks) after event; unfortunately subgroup data from Struik/RESCUE study does not have equivalent subgroup data; NIV appears to result in statistically 
s ignificant reduction in exacerbations in the persistent hypercapnic subgroup. Subgroup analysis excluding Cheung et all study (thought to be high risk of bias) does not 
s ignificantly affect estimates.  Overall less certainty of effects but desirable effects likely outweigh undesirable effects; given low certainty of evidence only 
conditional/week recommendation could be made, and this after considering patient values & preferences; acceptability, feasibility and cost of NIV in local setting. Future 
evidence could change this recommendation in the future.
Subgroup considerations
Major issue is  that subgroup of persistently hypercapnic patients from HOT-HMV appear to be most likely to benefit; this subgroup has statistically s ignficant reduction in 
hospitalizations compared to Struik/RESCUE data. 
Implementation considerations
Patients who are started early may not remain hypercapnic; suggest that the group most likely to benefit from NIV is  the group who remains hypercapnic 2-4 weeks after 
the episode, as seen in HOT-HMV. The panel recognized that the acceptability, feasibility, and costs of NIV vary greatly. For some patients and clinicans, the potential 
benefits (dyspnea, QOL, exercise tolerance; possible reduction in hospitalizations, though imprecise evidence) may not be worth it. This is  consistent with a conditional 
recommendation in GRADE. 
Monitoring and evaluation
Research priorities
1. Developing more accurate criteria for identifying patients who are likely to benefit from long-term NIV, such as severity of illness (hypothesis that treatment of higher 
PaCO2 at initiation will drive greater clinical benefits), trajectory of hypercapnia recovery after exacerbation (as some patients return to eucapnia more rapidly than others) 
and treatment response (e.g. early reduction in PaCO2 level after starting home NIV, with the hypothesis that greater reduction in PaCO2 will drive greater clinical benefit). 
 
2.Physiological and biological mechanisms of action of long-term NIV: physiological mechanisms determining reduction in PaCO2; the biological effects of PaCO2 reduction 
in chronic hypercapnia upon immune, pulmonary vasculature, and skeletal muscle; biological mechanisms determining reduction in exacerbation; and physiological 
mechanisms determining enhanced sleep quality.
 
3. The effects of NIV upon mental health and cognition upon patients, including effects upon HRQL post ARF, cognitive function post-AHRF, the relationship between HRQL 
and cognitive function upon adherence and acceptability of home NIV.
 
4. Health service delivery research to promote the delivery of post-acute NIV to the right patient at the right time and prevent the ‘overuse’ or ‘underuse’ of the treatment. 
 
5. Assessment of novel home treatments, e.g. high flow humidified nasal oxygen, that are capable of reducing PaCO2 in stable hypercapnic COPD patients.
ASSESSMENT
Problem
Is  the problem a priority?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ No
○ Probably no
○ Probably yes
● Yes
○ Varies
○ Don't know
The panel chose the PICO questions based upon 
their apparent relevance to clinical practice. 
Desirable Effects
How substantial are the desirable anticipated effects?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Trivial
● Small
○ Moderate
○ Large
○ Varies
○ Don't know
Desirable effects
Reduction in PaCO2, generally at rest (reduction 5 mmHg)
Undesirable effects
Slightly higher dyspnea scores in only 1 RCT
Consider sensitivity analysis excluding Lukacsovits 
2012 as measurements for PaO2 and PaCO2 were 
measured during NIV.
Murphy looked at high-intensity vs. high-pressure. 
Thus substantial questions therefore raised about 
the directness of the evidence. 
QUESTION
Should NIV with targeted normalization of PaCO2 levels vs. NIV without targeting normal PaCO2 level be used
for long-term NIV in COPD patients?
POPULATION: long-term NIV in COPD patients
INTERVENTION: NIV with targeted normalization of PaCO2 levels
COMPARISON: NIV without targeting normal PaCO2 level
MAIN
OUTCOMES:
Quality of Life; Dyspnea; FEV1; PaCO2; PaO2; 6MWD; Sleep Comfort;
SETTING:
PERSPECTIVE:
BACKGROUND:
CONFLICT OF
INTERESTS:
Minimal effect
Quality of life measured with SRI
Sleep quality
Exercise tolerance
The panel examined the studies from PICO 1 and 
the subgroup of studies which targeted 
normalization of CO2 vs. studies which did not 
target normalization. The subgroup which targeted 
normal CO2 demonstrated more benefit for NIV (Ie 
effect s izes were larger in studies which targeted 
normal CO2). 
The panel judged overal there may be a small 
benefit to targeting normal CO2.
Undesirable Effects
How substantial are the undesirable anticipated effects?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Large
○ Moderate
○ Small
● Trivial
○ Varies
○ Don't know
Desirable effects
Reduction in PaCO2, generally at rest (reduction 5 mmHg)
Undesirable effects
Slightly higher dyspnea scores in only 1 RCT
Minimal effect
Quality of life measured with SRI
Sleep quality
Exercise tolerance
Trival undesirable effects-- s lightly higher dypnea 
scores in a s ingle study. 
Certainty of evidence
What is  the overall certainty of the evidence of effects?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
● Very low
○ Low
○ Moderate
○ High
○ No included studies
Very low certainty evidence. Less certainty as well because studies were 
generally short-term, without measuring effects upon mortality, 
hospitalizations, exacerbations.
Values
Is  there important uncertainty about or variability in how much people value the main outcomes?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Important uncertainty or
variability
● Possibly important uncertainty
or variability
○ Probably no important
uncertainty or variability
○ No important uncertainty or
variability
Exacerbations, dyspnea, and quality of life are among the most important 
outcomes in patients with COPD. Symptom relief was generally found to be 
more important than adverse events. PMID: 30002103
Balance of effects
Does the balance between desirable and undesirable effects favor the intervention or the comparison?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Favors the comparison
○ Probably favors the
comparison
○ Does not favor either the
intervention or the comparison
● Probably favors the
intervention
○ Favors the intervention
○ Varies
○ Don't know
While very low certainty of evidence of a small 
benefit, the anticipated harms are trivial, meaning 
the evidence probably favours the intervention.
Resources required
How large are the resource requirements (costs)?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Large costs
○ Moderate costs
● Negligible costs and savings
○ Moderate savings
○ Large savings
○ Varies
○ Don't know
Implimenting higher intensity CO2 reduction 
required more time in hospital in one study, 
though admittedly limited evidence. No formal 
analysis of cost in any studies. 
Certainty of evidence of required resources
What is  the certainty of the evidence of resource requirements (costs)?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
● Very low
○ Low
○ Moderate
○ High
○ No included studies
Cost effectiveness
Does the cost-effectiveness of the intervention favor the intervention or the comparison?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Favors the comparison
○ Probably favors the
comparison
○ Does not favor either the
intervention or the comparison
○ Probably favors the
intervention
○ Favors the intervention
○ Varies
● No included studies
Given lack of certainty of benefits, lack of evidence 
for costs, the task force could not provide a 
judgement of the cost-effectiveness of targeting 
normalization of CO2 levels. If targeting normal 
CO2 was technically challenging in a given setting, 
it may not be cost-effective. 
Equity
What would be the impact on health equity?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Reduced
○ Probably reduced
● Probably no impact
○ Probably increased
○ Increased
○ Varies
○ Don't know
Probably no impact upon equity when 
implementing in a patient popualtion already 
receiving NIV.
Acceptability
Is  the intervention acceptable to key stakeholders?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ No
○ Probably no
○ Probably yes
● Yes
○ Varies
○ Don't know
This approach is  probably acceptable to clinicians, 
who apprecaite having a clear "target" for CO2. It 
makes physiologic sense to clinicians as well. 
Patients probably have no issues with acceptability 
unless settings need to be very high to achieve 
normal CO2; in such cases high-intensity NIV may 
not be acceptable.
Feasibility
Is  the intervention feasible to implement?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ No
○ Probably no
○ Probably yes
● Yes
○ Varies
○ Don't know
In s ituations where NIV is  planned, more  targeting 
a s ignificant reduction of CO2 is  feasible, though 
actual normalization of CO2 levels is  unlikely to be 
achieved for many patients, based upon the 
results of the included studies, which did not 
demonstrate complete normalization of CO2.
SUMMARY OF JUDGEMENTS
JUDGEMENT
PROBLEM No Probably no Probably yes Yes Varies Don't know
DESIRABLE EFFECTS Trivial Small Moderate Large Varies Don't know
UNDESIRABLE EFFECTS Large Moderate Small Trivial Varies Don't know
CERTAINTY OF EVIDENCE Very low Low Moderate High
No included
studies
VALUES
Important
uncertainty or
variability
Possibly
important
uncertainty or
variability
Probably no
important
uncertainty or
variability
No important
uncertainty or
variability
BALANCE OF EFFECTS
Favors the
comparison
Probably favors
the comparison
Does not favor
either the
intervention or the
comparison
Probably favors
the intervention
Favors the
intervention
Varies Don't know
RESOURCES REQUIRED Large costs Moderate costs
Negligible costs
and savings
Moderate savings Large savings Varies Don't know
CERTAINTY OF EVIDENCE
OF REQUIRED
RESOURCES
Very low Low Moderate High
No included
studies
COST EFFECTIVENESS
Favors the
comparison
Probably favors
the comparison
Does not favor
either the
intervention or the
comparison
Probably favors
the intervention
Favors the
intervention
Varies
No included
studies
EQUITY Reduced Probably reduced
Probably no
impact
Probably increased Increased Varies Don't know
ACCEPTABILITY No Probably no Probably yes Yes Varies Don't know
FEASIBILITY No Probably no Probably yes Yes Varies Don't know
TYPE OF RECOMMENDATION
CONCLUSIONS
Recommendation
The ERS TF suggests titrating long-term NIV to normalize or reduce PaCO2 levels in patients with COPD (conditional recommendation, very low certainty evidence).
Justification
We make a conditional recommendation due to the minimal potential harms of targeted normalization of CO2 and it is  recognized that this is  unlikely to be achieved in 
many patients.  While high-intensity NIV may or may not have benefits, this is  the approach most commonly used in many centres, and thus this is  probably the most 
acceptable approach for many clinicinans. Setting NIV to target a reduction in PaCO2 may require more time spent in hospital and therefore possibly increase costs and 
decrease feasibility of NIV. Recognizing the lack of compelling evidence, the panel made a conditional recommendation for high-intensity NIV, but low-intensity approaches 
may also be acceptable and useful in many patients.
Subgroup considerations
Strong recommendation against
the intervention
Conditional recommendation
against the intervention
Conditional recommendation for
either the intervention or the
comparison
Conditional recommendation
for the intervention
Strong recommendation for the
intervention
○ ○ ○ ● ○
Implementation considerations
It is  likely reasonable for initially aim for a normal CO2 in most patients, given the lack of harms and the possible, though very small, benefits with such an approach. If 
achieving normal CO2 was very difficult or the settings very high and uncomfortable for the patient, tartgeting normal CO2 may  not worth lots of effort to achieve. 
Monitoring and evaluation
Research priorities
1) The impact of NIV ventilator strategy targeted to maximise PaCO2 reduction compared to conventional ventilator modes on long-term clinical outcomes (i.e. 
hyperinflation, exacerbations, cardiovascular complications, hospitalisations, survival, costs, patient’s adherence).
ASSESSMENT
Problem
Is  the problem a priority?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ No
○ Probably no
○ Probably yes
○ Yes
○ Varies
● Don't know
Question about variable modes is  clearly 
important, however most modes are not studied, 
All studies in the systematic reviewer compared 
volume-targeted ventilator modes. The number of 
studies looking at these modes may reflect the 
desire of industry to find evidence to support 
these modes, rather than patient or clinician 
needs. Safety is  the priority question given that 
these modes could result in hypoventilaion or 
result in large leaks. 
The studies included in PICOs 1-3 generally used 
fixed-pressure modes, making the applicability of 
evidence for these questions uncertain for auto-
titrating modes: there is  no long-term evidence of 
the impact of these modes upon mortality, 
hospitalizations etc. 
Desirable Effects
QUESTION
Should Adaptive volume-targeted NIV vs. conventional NIV be used for long-term NIV in patients with COPD?
POPULATION: long-term NIV in patients with COPD
INTERVENTION: Adaptive volume-targeted NIV
COMPARISON: conventional NIV
MAIN
OUTCOMES:
Quality of Life; Sleep quality; Exercise tolerance; PaCO2; Oxygenation;
SETTING:
PERSPECTIVE:
BACKGROUND:
CONFLICT OF
INTERESTS:
How substantial are the desirable anticipated effects?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
● Trivial
○ Small
○ Moderate
○ Large
○ Varies
○ Don't know
Desirable effects
Small improvement in short-term (~2-3 months) QoL 
PCO2
Undesirable effects
Little to no effect
Sleep quality
Exercise tolerance
Unknown
Mortality
Hospitalizations
Exacerbations
Undesirable Effects
How substantial are the undesirable anticipated effects?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Large
○ Moderate
○ Small
● Trivial
○ Varies
○ Don't know
Desirable effects
Small improvement in short-term (~2-3 months) QoL 
PCO2
Undesirable effects
Little to no effect
Sleep quality
Exercise tolerance
Unknown
Mortality
Hospitalizations
Exacerbations
Potential harms not included in short-term studies 
included in meta-analysis. 
Theoretical risk of large leaks and hypoventilation 
with auto-titrating modes which may not be evident 
in short-term studies. Risks of impacting mortality, 
hospitalizations, and exacerbations. 
Certainty of evidence
What is  the overall certainty of the evidence of effects?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Very low
● Low
○ Moderate
○ High
○ No included studies
Generally  low certainty of pooled evidence. Substantial uncertainty about the effectiveness 
across algorithms, machines, makes and models.
Values
Is  there important uncertainty about or variability in how much people value the main outcomes?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Important uncertainty or
variability
● Possibly important uncertainty
or variability
○ Probably no important
uncertainty or variability
○ No important uncertainty or
variability
Exacerbations, dyspnea, and quality of life are among the most important 
outcomes in patients with COPD. Symptom relief was generally found to be 
more important than adverse events. PMID: 30002103
Balance of effects
Does the balance between desirable and undesirable effects favor the intervention or the comparison?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Favors the comparison
○ Probably favors the
comparison
● Does not favor either the
intervention or the comparison
○ Probably favors the
intervention
○ Favors the intervention
○ Varies
○ Don't know
Auto-titrating modes may be more beneficial in 
those in the setting of exacerbation or in the time 
of titration when trying to decide on levels of 
support.
Despite possible improvement in short-term QOL, 
there is  no clear benefit to use overall, and 
ongoing safety concerns about leaks and 
hypoventilation in the long-term.
Resources required
How large are the resource requirements (costs)?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Large costs
○ Moderate costs
○ Negligible costs and savings
○ Moderate savings
○ Large savings
● Varies
○ Don't know
It will cost more to upgrade from an existing 
machine. For a new machine, the price of a 
ventilator with these capabilities will vary, but 
could be anything from no extra cost to expensive 
depending on make, model, funding strategy, etc. 
Certainty of evidence of required resources
What is  the certainty of the evidence of resource requirements (costs)?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Very low
○ Low
○ Moderate
○ High
● No included studies
No real evidence to address cost. 
Cost effectiveness
Does the cost-effectiveness of the intervention favor the intervention or the comparison?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Favors the comparison
○ Probably favors the
comparison
○ Does not favor either the
intervention or the comparison
○ Probably favors the
intervention
○ Favors the intervention
○ Varies
● No included studies
Given lack of evidence for benefits and harms, lack 
of certianty around costs it is  difficult to assess 
cost-effectiveness.
Equity
What would be the impact on health equity?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ Reduced
○ Probably reduced
○ Probably no impact
Cost is  higher so implementing these modes may 
increase inequity, hightening disparities between 
those with financial resources and those without. 
May reduce inequity as patients who do not have 
○ Probably increased
○ Increased
● Varies
○ Don't know
access to a s leep laboratory to titrate NIV may 
benefit from some titration of NIV settings, though 
this question has not been studied in the existing 
clincal trials .
Acceptability
Is  the intervention acceptable to key stakeholders?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ No
○ Probably no
○ Probably yes
● Yes
○ Varies
○ Don't know
Compliance between adaptive VTPCV and conventional NIV were not 
s ignificantly different in 5 studies (Crisafulli 2009, Oscroft 2010, Oscroft 2014, 
Ekkernkamp 2014, Storre 2014) which used data directly from the NIV devices. 
Patient self-reported toleance was not s ignificantly different in 2 studies ( 
Oscroft 2010, Storre 2014). Self-reported comfort was not different in 2 
studies (Crisafulli 2009, Oscroft 2010). One study (Nilius 2017) used a 
questionnaire to assess acceptability, again finding no differences.
Overal doesn't seem to be any differences in 
acceptability of these modes vs. conventional fixed 
pressure modes. 
Feasibility
Is  the intervention feasible to implement?
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS
○ No
○ Probably no
○ Probably yes
● Yes
○ Varies
○ Don't know
Probably feasible, if ventilators already have these 
modes included. If not, would be less feasible. 
SUMMARY OF JUDGEMENTS
JUDGEMENT
PROBLEM No Probably no Probably yes Yes Varies Don't know
DESIRABLE EFFECTS Trivial Small Moderate Large Varies Don't know
UNDESIRABLE EFFECTS Large Moderate Small Trivial Varies Don't know
CERTAINTY OF EVIDENCE Very low Low Moderate High
No included
studies
VALUES
Important
uncertainty or
variability
Possibly
important
uncertainty or
variability
Probably no
important
uncertainty or
variability
No important
uncertainty or
variability
Does not favor
BALANCE OF EFFECTS
Favors the
comparison
Probably favors
the comparison
either the
intervention or
the comparison
Probably favors
the intervention
Favors the
intervention
Varies Don't know
RESOURCES REQUIRED Large costs Moderate costs
Negligible costs
and savings
Moderate savings Large savings Varies Don't know
CERTAINTY OF EVIDENCE
OF REQUIRED
RESOURCES
Very low Low Moderate High
No included
studies
COST EFFECTIVENESS
Favors the
comparison
Probably favors
the comparison
Does not favor
either the
intervention or the
comparison
Probably favors
the intervention
Favors the
intervention
Varies
No included
studies
EQUITY Reduced Probably reduced Probably no impact
Probably
increased
Increased Varies Don't know
ACCEPTABILITY No Probably no Probably yes Yes Varies Don't know
FEASIBILITY No Probably no Probably yes Yes Varies Don't know
TYPE OF RECOMMENDATION
CONCLUSIONS
Recommendation
The ERS TF suggests using fixed pressure support mode as first-choice ventilator mode in patients with COPD using long-term NIV (conditional recommendation, very low 
certainty evidence).
Justification
While there may be benefits based upon the included short-term studies,  further research is  needed to demonstrate safety, especially given potential safety concerns 
Strong recommendation against
the intervention
Conditional recommendation
against the intervention
Conditional recommendation for
either the intervention or the
comparison
Conditional recommendation for
the intervention
Strong recommendation for the
intervention
○ ● ○ ○ ○
about dynamic auto-changes of the ventilator resulting in leaks or hypoventilation.  Given that virtually all studies in other questions (PICO 1, 2, 3) used fixed-pressure 
modes, and that the PICO recomendations are thus based upon studies using this mode, it is  unclear if the existing evidence would also apply to ventilators using these 
auto-titrating modes. Lastly, changing to these auto-modes may require purchase or exchange of new ventilators, reducing feasibility. While these modes may theoretically 
be useful to titrate without monitoring, until the safety of such approach is  demonstrated the risks of unmonitored titration are unclear and this is  not recommended.
Overall,  given the uncertainty of long-term benefits, difficulty applying the evidence and recommendations from PICOs 1-3, the panel made a conditional recommendation 
against using auto-titrating modes as the initial mode of ventilation. However, conditional recommendation also means there may be some circumstances where these 
modes are considered for use, though the panel did not identify any such s ituations. 
Subgroup considerations
Implementation considerations
Monitoring and evaluation
Research priorities
1) The role of adaptive/auto-titrating modes to improve the long-term outcome of COPD, acute exacerbation vs chronic stable hypercapnic COPD and optimization of 
overnight ventilation, especially in specific subgroups in which ventilatory requirements may vary substantially overnight.
 
2) The assessment of auto-EPAP modes (in addition to adaptive/auto-titrating modes) in the sub-group of patients with COPD-OSA overlap syndrome
 
3) The clinical efficacy and cost effectiveness of of auto-titrating modes in the inpatient vs outpatient settings avoiding the need for hospitalization to initiate NIV, thereby 
increasing access to NIV.
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
 
Supplementary Figure 1: PRISMA Diagram of Included Studies 
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